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ABSTRACT
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in the
U.S. and worldwide. Atherosclerosis, the buildup of plaque in the arteries, is a
common cause of CVD. For many years, research in atherosclerosis was focused
on lipid metabolism and the accumulation of low-density lipoprotein in the arteries.
While this research set public health guidelines for lipid management, lipid
concentration was not the only factor influencing atherosclerosis and CVD events.
Many scientists, as far back as the 1850’s recognized the role of inflammation in the
progression of atherosclerotic disease. The continuous low levels of immune
activation in the body contribute to atherosclerosis. Research in animal models and
epidemiologic studies have shown the involvement of both the innate and the
adaptive immune systems in plaque development and to elucidate the roles of
monocytes and T cells. In addition to animal studies and epidemiologic research,
CVD and atherosclerotic research has extended to genetic analysis in the search for
associations with risk factors and outcomes.
The first chapter is a review of the literature studying the immune system’s
involvement in atherosclerosis. Beginning with an examination of the impact of
CVD and atherosclerosis, the basic pathophysiology, and the involvement of the
innate and adaptive immune systems through animal models and epidemiology.
Some of the significant cohort studies in CVD and genome wide association studies
are also discussed.
Chapter 2 examines the associations of soluble interleukin 2 receptor alpha
(sIL-2Rα) with clinical events in the Cardiovascular Health Study and genetic
variants. Interleukin 2 (IL-2) and its receptor regulate both tolerance and immunity,
IL-2 induces the proliferation and differentiation of T cells, part of the adaptive
immune system. The results showed an association between sIL-2Rα and CVD
events. The genome-wide association study found 52 variants to be significantly
associated with sIL-2Rα in European Americans.
Chapter 3 assesses the involvement of the innate immune system in
atherosclerosis through the associations of soluble CD163 (sCD163). CD163 is a
marker of macrophage activation, specifically associated with M2 macrophages. In
CHS, sCD163 levels were analyzed for associations with cardiovascular events and
genetic variants. sCD163 was found to be associated with CVD risk factors and
with cardiovascular events. In a genome-wide association study six variants in
European Americans and three variants in African Americans were found to be
significant.
Chapter 4 summarizes the results and discusses some bench to bedside
translational science already seen in atherosclerosis treatment and prevention.
Continued investigation of markers of T-cell and monocyte differentiation in animal
models and cohort studies may lead to opportunities for the prevention of
atherosclerosis and/or treatment through an increased understanding of the biology
and genetics of the innate and adaptive immune.
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CHAPTER 1: Innate and Adaptive Immunity in Cardiovascular Disease: A
Review of the Pathobiology of Immunity in Atherosclerosis
Cardiovascular Disease is a major cause of morbidity and mortality in
the U.S. and Worldwide.
Cardiovascular disease (CVD) is a broad term covering a family of diseases
linked by common risk factors, many of which are caused by atherosclerosis.
Atherosclerosis plays a major role in coronary heart disease, peripheral artery
disease, and myocardial infarction, some forms of heart failure, stroke, and
hypertension, and contributes to poor outcomes in diabetes, chronic kidney disease,
vascular dementia, and others included in ICD10 codes 100-199. CVD is the
leading cause of death throughout the world, accounting for more than 17.5 million
deaths in 2012; 31% of all global deaths [1]; more deaths than all forms of cancer
combined. In the United States in 2013, CVD was the underlying cause of death
for over 800,900 deaths and is the leading cause of death in both women and men
over the age of 65 [2].
CVD, is both a huge burden on the health care system and a huge economic
burden. From 2011 to 2012, the average annual direct and indirect cost of CVD in
the United States was estimated at $316.6 billion [2]. These costs included direct
costs of physicians, hospitals, medication and health care, estimated at $193.1
billion, as well as the indirect costs of lost productivity and mortality, estimated at
$123.5 billion [2]. Projections for 2030 indicate that 43.9% of the US population
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will have some form of CVD and total costs associated with CVD will increase to
more than $1.2 trillion [2].
From 1979 to 2011 the US saw a large decline in deaths attributable to
CVD; mortality rates dropped 52% in men and 49% in women between 1980 and
2002[3]. Ford et al. found that that 47% of the decrease was due to improved
treatment and therapies, including secondary preventive treatments, initial treatment
of myocardial infarctions, heart failure treatments and others [4]. Forty-four
percent of the decline was due to changes in risk factors; reductions in total
cholesterol, systolic blood pressure and smoking, along with increased physical
activity [4]. The most consistent declines were in adults ≥65 years of age between
1979 and 1989. Despite this success, the three subsequent decades showed little
change in the mortality rates. This was especially true in both men and women
between the ages of 35-54. While there are fewer studies of younger people, and
younger women are particularly understudied, it is possible that one of the
mechanisms contributing to the sluggish decline of CVD mortality in this group is
due to increased risk factors.
Atherosclerosis is an underlying cause of CVD; preventing atherosclerosis
by reducing risk factors may prevent 90% of all CVD. Exercise, weight loss,
healthy eating, limited alcohol consumption, the avoidance of smoking, treatment of
hypertension and diabetes are all beneficial in the prevention of atherosclerosis, and
have the potential to mitigate a major portion of the morbidity, mortality, and health
2

care burden of atherosclerotic CVD. However, much remains to be understood
about the underlying pathophysiology of CVD in general and atherosclerosis in
particular if complete eradication is our goal.
The General Pathophysiology of Atherosclerosis.
The term atherosclerosis, from the Greek words athero meaning gruel or
porridge and sclerosis meaning hardening specific to an artery, was first introduced
in 1829 by the French surgeon, Jean Lobstein [5]. Over the years, our
understanding of atherosclerosis, its development, and complications has emerged
from studies of animal models, plus basic research, clinical research and
epidemiology. Although until recently viewed as solely a cholesterol storage
problem with lipid accumulation clogging the arteries and culminating in a heart
attack, it was Virchow who first noted inflammation as the beginning of
atherosclerosis in 1859 [6]. ‘I have therefore felt no hesitation in siding with the
old view in this matter, and in admitting an inflammation of the inner arterial coat
to be the starting point of the so-called atheromatous degeneration…’[7]. Initially,
Virchow’s hypothesis of atherosclerosis as an inflammatory disease was considered
baseless, while his notion of cellular proliferation in the progression of atheromas
(blister-like bulges in the arterial wall with central lipid pools) was acknowledged.
Duguid [8], in the late 1940’s along with Mustard and Packham [9], French[10] in
the mid 1960’s, and Ross[11, 12] in the mid 1970’s modified and extended those
early observations of an association between inflammation and atherosclerosis.
3

The beginning of an atherosclerotic lesion can be found in infants as fatty
streaks, consisting of lipid filled macrophages and T lymphocytes in the intima of
arteries [13]. These fatty streaks may not progress and in some cases may even
regress. Autopsies of young soldiers from the Korean War (average age 22) found
that greater than 70% had some atherosclerosis in their coronary arteries [14]. Over
one hundred years ago, the cholesterol hypothesis of atherosclerosis was born when
Anitschokow published his work on arterial lesions seen in rabbits fed a high
cholesterol diet [15, 16]. Anitschkow continued his work with rabbits documenting
the cholesterol accumulation in the arteries, foam cell development, white cell
involvement, and the conversion of fatty streaks to the mature form of
atherosclerotic lesion, the atherosclerotic plaque. While other laboratories
confirmed Anitschokow’s results with further experiments in rabbits [17], many
scientists at the time were working with other animals including dogs and rats, and
were unable to substantiate the cholesterol hypothesis with the prevailing
assumption being that atherosclerosis was considered a disease of aging, a chronic,
inevitable progression. Although Anitschokow believed that there could be no
atherosclerosis without the deposition of cholesterol, his understanding evolved
when he noted that blood pressure and arterial changes were significant factors in
atheroma development, leading to his ‘combination theory’ of atherosclerosis [15].
Today, the importance of cholesterol and hypertension in atherosclerosis are no
longer questioned and the controls of hypercholesterolemia and blood pressure have
been shown to reduce morbidity and mortality of CVD. Since the early 1980’s
4

animal experiments, clinical studies and epidemiological research have focused on
lipid metabolism and cholesterol deposition, and what we now recognize as the
inflammatory response to such deposition, in the development and progression of
atherosclerosis.
Basic and Clinical Research: Atherosclerosis as an Inflammatory
Disorder.
While atherosclerotic plaques or atheromas may develop in the intima, or
innermost layer, of many large arteries from the aorta to the coronaries, the arterial
sites located near branch points with low shear stress [18, 19] (Figure 1) are the
most common sites.

5

Figure 1: Fatty streak development Ross, R. NEJM 1999; 340:115-126
Plaque Development
Plaque development and progression begins in adolescence and can last > 40
years [20, 21]. The development of fatty streaks begins with the accumulation of
lipid particles, primarily low-density lipoproteins (LDL), in the arterial intima.
When the concentration of LDL particles exceeds the capacity to clear them from

6

the intima, they incorporate into the extracellular matrix and initiate activation of
the innate immune system and the atherosclerotic process begins (Figure 2).

Figure 2: Inflammation and Atherosclerosis
Modification of these LDL particles to oxidized LDL (oxLDL) by activated
endothelial cells [22] leads to the expression of leukocyte adhesion molecules,
vascular cell adhesion molecule-1 and P-selectin, enabling lymphocytes and
monocytes to preferentially adhere.
The Key Role of Monocytes/Macrophages.
The adherent monocytes respond to chemokines, monocyte chemoattractant
proteins (MCP-1 and CCL2), and migrate into the intima [23]. Once exposed to
7

macrophage-stimulating factor, the monocytes differentiate into macrophages. We
currently recognize three subsets of macrophages found in human circulation,
differentiated by their expression of CD14 and CD16 receptors. M1 macrophages,
or “classically” activated macrophages, constitute the majority of macrophages
(~90%) and are CD14++CD16-; CD14++CD16+ macrophages are classified as
intermediate macrophages, and “alternatively” activated or M2 macrophages
(CD14+CD16++) [24-26]. Pro-inflammatory M1 macrophages are phagocytic and
secrete interleukin-1β, tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), and
IL-12[27] among other mediators of inflammation. M2 macrophages produce the
regulatory cytokine IL-10 and modulate inflammation. Both types of macrophages
bind and internalize oxLDL and are capable of forming foam cells. If the transport
of the lipids or macrophage egress from the intima is impaired there is excess lipid
accumulation which results in cell death and the release of cholesterol and
inflammatory cytokines; further perpetuating the recruitment of monocytes,
continued chronic inflammation, and plaque formation [28]. Macrophages have the
ability to switch their phenotype from M1 to M2 and vice versa depending on
specific cytokine signals [29, 30]. M1 macrophages have long been implicated in
the atherosclerotic process and have been identified in plaques as well [31].
However, it wasn’t until 2007 when Amine Bouhel et al. examined M2 macrophage
marker RNA in the plaques of 27 patients that M2 cells were identified in plaques
[29]. Histological analysis of plaques from more than 80 patients found that M2
macrophages were localized to more stable areas of the lesions while M1
8

macrophages were predominant in symptomatic plaques [32]. Additionally, the
presence of CD163, a macrophage specific receptor found on M2 macrophages
[33], was inversely related to the progression of atherosclerosis [32]. Macrophage
plasticity and the switch from pro-inflammatory M1 macrophages to immune
modulating M2 macrophages illustrates the complex nature of atherosclerosis.
While atherosclerosis is caused by continued inflammation, it may be that impaired
immune regulation is also a contributing factor.
The Emerging Role of the Adaptive Immune System.
The initial inflammatory response in atherosclerosis begins with the innate
immune system, followed by the involvement of the adaptive immune system. The
cells that comprise the innate or non-specific immune system include macrophages,
neutrophils, dendritic cells, and natural killer cells, among others. These cells are
always present and mobilize when an infection occurs. Adaptive immunity is
composed of humoral immunity mediated by B cells, plasma cells, and antibodies;
and cell mediated immunity driven by T lymphocytes. Dendritic cells take up
oxLDL, other LDL particles, and heat shock proteins, present these antigens to
naïve T cells in peripheral lymphoid organs, and thereby generate an adaptive
immune response[34-38]. T cell recruitment is similar to monocyte recruitment and
involves both adhesion molecules and chemokines [39]. The naïve T cells
differentiate to T helper cells (Th CD4+) and cytotoxic T cells (Th CD8+). T helper
cells differentiate further becoming Th1, Th2, Th17, and T regulatory cells (Treg)
9

[40, 41] (Figure 3). T cells are not as prominent in the atheroma as macrophages;
the macrophage/T cell ratio ranges from 4:1 to 10:1 [40].

Figure 3: T cell Differentiation: Cell Mol Immunol. 2010 May;7(3):182-9.

T Helper Type 1 Cells Play a Major Role in Atherosclerosis.
Analysis of human atherosclerotic plaques has shown that CD4+ T cells are
present in higher numbers than CD8+ T cells [42]. The T cells are usually found in
the shoulder region of a plaque near major histocompatibility complex (MHC) class
II expressing macrophages and dendritic cells, suggesting a continuing
inflammatory response in the atheroma [43-46]. Th1 and Th2 cells have been the
most investigated and well characterized of the T cell subsets. Differentiation of
naïve CD4+ T helper cells requires three sequential signals; first, the T cell receptor
10

is stimulated, next dendritic cells produce cytokines, and last, co-stimulatory
molecules on the cell surface of dendritic cells are activated [47]. Differentiation of
naïve T cells depends upon the cytokines released. IL-12 is an important
connection between the innate and adaptive immune systems. Produced by
monocytes, macrophages, and dendritic cells during infection, IL-12 upregulates the
production of IFN-γ and biases the differentiation of naïve CD4+ T cells to
proinflammatory Th1 cells while reducing the production of anti-inflammatory
cytokines IL-4, IL-5, and IL-13 [48, 49]. IL-12 and interferon γ (INF-γ) work by
activating signal transducer and activator of transcription (STAT)-4 and T-box
transcription factor TBX21 [47, 49]. The activation of TBX21 allows the continued
expression of INF-γ, the predominate pro-inflammatory cytokine produced by Th1
cells, further activation of macrophages and endothelial cells with increased
expression of pro-inflammatory cytokines and adhesion molecules, and the down
regulation of Th2 cytokines IL-4 and IL-5 [39, 50]. Differentiation of Th2 cells
initiated by IL-4, activates the expression of STAT-6, in turn promoting T-cell
specific transcription factor GATA3. GATA3 upregulates the expression of both
IL-4 and IL-5 while inhibiting the expression of IFN-γ thus promoting the
differentiation of Th2 cells [47].
Both human and animal studies have identified Th1 cells as the primary driver of
atherosclerosis with Th1 cells seen as the dominate cell type in lesions [51]. In
1999 de Boer et al. reported that T cell clones isolated from a human aortic plaque
contained 17% Th1 cells but only 2% Th2 cells. Mouse studies have provided
11

compelling evidence for the pro-atherogenic function of Th1 cell, work by Huber et
al. showed the importance of Th1 cells in the development of atherosclerosis [52,
53]. When Huber et al. injected both atherosclerosis-susceptible and resistant
strains of mice with weekly doses of IL-6 they found a 2 to 5 fold increase in
atherosclerotic lesion size [53]. Class II major histocompatibility complex (MHC)
molecules regulate T cell responses; the mouse has two different MHC molecules,
IA and IE. The atherosclerotic–susceptible mouse strain only expresses the IA
molecules with Th1 cells being the predominant cell type, suggesting that
atherosclerotic susceptibility may be due to T cell differentiation biased toward the
Th1 cell type, while IE expression leads to a Th2 cell bias. The proatherogenic
cytokine IFN-γ is produced by Th1 cells, while Th2 cells produce the
antiatherogenic cytokine IL-4 suggesting that pro-inflammatory cytokine expression
is actively involved in plaque development. Studies in the early 1990’s on sections
of human atherosclerotic lesions found that T cells formed complexes with
macrophages and that these interactions between the innate and adaptive immune
systems are integral in the pathogenesis of atherosclerosis [54]. Although
lipoprotein metabolism and immune function differ between mice and humans,
atherosclerosis prone mice have provided information furthering the understanding
of the atherosclerotic process. Mice lacking either the LDL receptor (LDLR) or
Apoliportotein E (ApoE), an integral component of lipoprotein metabolism, have
been commonly used [55]. When fed a high fat diet, mice deficient in the LDLR
(LDLR-/-) develop large atherosclerotic lesions associated with severe
12

hypercholesterolemia. ApoE deficient (ApoE-/-) mice also develop atherosclerotic
lesions morphologically similar to early human lesions when fed a high fat diet.
When these mice are given INF-γ, they produce larger and more numerous
atherosclerotic lesions than control mice. Conversely, mice deficient in INF-γ or the
INF-γ receptor have fewer lesions [56-59]. Lee et al. showed that if ApoE-/- mice
were injected with IL-12 they would develop plaques even when fed a normal diet
[60]. Davenport and Tipping found that the deletion of the IL-12 encoding gene in
mice prohibited early lesion development [61] as did Hauer et al. when they
vaccinated mice against IL-12 [62]. Further evidence of the involvement of Th1
cells in atherosclerosis comes from research done in ApoE-/- mice with IL-18, a Th1
promoting cytokine. Elhage et al. bred a mouse that was both ApoE and IL-18
deficient and found reduced atherosclerotic lesion size when compared to wild type
mice in spite of the double knockout mice having significantly higher levels of both
serum cholesterol and triglycerides [63]. When Whitman et al. injected ApoE-/mice with IL-18 over a period of thirty days, while being fed a normal diet, they
found that atherosclerotic lesion size was increased two fold compared to animals
not administered IL-18. Buono et al. bred a mouse line that was deficient in both
the LDLR and Tbx21, which codes for the T-bet transcription factor required for
Th1 differentiation and regulation of Th1, Th2 balance in inflammation. The
amount of atherosclerosis in the Tbx21 deleted Ldlr-/- mice was significantly less
than that in the mice that were only Ldlr deficient [64]. Additionally, the Tbx21
deficiency caused a switch of the dominant cellular phenotype to Th2 cells [51]. In
13

a study of 28 patients with acute coronary syndrome, Methe et al. found there were
significantly more Th1 cells when compared to controls in patients with stable
angina and that elevated Th1 cell counts were predictive of cardiovascular events
[65].
Th2 Cell Involvement in Atherosclerosis is Less Clear.
While the role of Th1 cells in plaque development has been clearly defined
as pro-atherogenic with both Th1 cells and their associated cytokines having been
identified in human atherosclerotic plaques [51], the role of Th2 cells is not as well
understood. Dendritic cells stimulate the differentiation of naïve T cells to Th2
cells through the production of IL-6/IL-13 and the interaction of the OX40 receptor
on the T cell with the OX40 ligand on the antigen presenting dendritic cell [50].
The Th2 cells produce IL-5, IL-4, IL-10 and IL-13 and activate B cell dependent
responses [66, 67]. The transcription of GATA-3, the master regulator of Th2 cells,
is triggered by the IL-4 dependent stimulation of STAT-6 and suppresses the
expression of IFN-γ [50] while upregulating IL-5 expression. Therefore, the Th2
responses would seem to modulate inflammation, the pro-atherogenic effects of Th1
cells, and provide atheroprotection. However, the role of Th2 cells and their
responses has proven to be more controversial depending upon the stage of lesion
development, the site of the lesion, and the experimental model. IL-4 has been
shown to have both anti-atherogenic and pro-atherogenic affects in a number of
murine studies [53, 61, 68]. Binder et al. showed in a murine model that IL-5
14

deficient mice had accelerated atherogenesis and that Th2 responses taken together
not only are anti-atherogenic but also reduced lesion size[69-71]. IL-5 also
promotes B-1 cell development, increasing the production of IgM antibodies which
may inhibit foam cell formation and the initiation of an atherosclerotic lesion [72].
IL-10 is an important regulator of immunity, balancing the Th1 and Th2 response
[73-75]. Murine studies of double knockout mice, ApoE-/- and IL-10-/-, found
increased LDL cholesterol levels, increased numbers of Th1 cells, and increased
lesion size when compared to ApoE-/- mice [76]. In addition to the effect IL-10 has
on lesion size, it also seems to stabilize plaques [67]. The role of IL-13 in
atherosclerosis has not been investigated in depth; however, work by Cardil-Reis et
al. in LDLR-/- mice showed that when injected intraperitoneally with IL-13 the mice
had decreased expression of cellular adhesion molecules and decreased numbers of
macrophages in atherosclerotic lesions (with a biasing toward M2 macrophages)
when compared to controls [77]. A deficiency in IL-13 resulted in accelerated
atherosclerosis.
Contributions of other T Cell Subsets to Atherosclerosis.
The contribution of Th17 cells to atherosclerosis is unclear. Th17 cells
promote both pro-inflammatory and anti-inflammatory responses based on the
environment. The association of Th17 cells with inflammatory autoimmune
diseases including rheumatoid arthritis and inflammatory bowel disease is well
documented [78]. However, the data on the role Th17 cells and their signature
15

cytokine, IL-17, is conflicting; both Th17 and Il-17 expression have been observed
in human [79] and murine lesions [80]. A study by Eid et al. on patients with
coronary atherosclerosis showed that IL-17 and INF-γ act together to promote
proinflammatory responses in vascular smooth muscle cells [81]. Further research
by Erbel et al. found that the secretion of IL-17A was associated with plaque
inflammation and destabilization [82]. Conflicting research indicates that increased
levels of IL-17 reduce macrophage numbers and promote fibrosis of the plaque [79,
83].
Regulatory T cells (Tregs) are crucial in maintaining the balance between
Th1 and Th2 cells by suppressing immune responses [84]. IL-10 and TGFβ are the
primary cytokines responsible for the antiatherogenic effects of Treg cells. Mouse
models using both mice genetically altered for reduced Tregs and mice vaccinated
against Tregs have both shown increased atherosclerosis [85-88]. Tregs are
atheroprotective by not only inhibiting T cell activation, but also, by inhibiting
foam cell formation and stimulating anti-inflammatory M2 macrophage
differentiation [89, 90]. De Boer et al. examined atherosclerotic vessel fragments
from 42 patients for the presence of Treg cells and found their presence in all stages
of lesion development (0.5-5%) [91]. Il-2 plays a crucial role in T cell development
and protective immunity, as well immune modulation moderated by Treg cells [92].
Treg cells, like all T cells, express the alpha receptor of IL-2 (IL-2Rα). In addition
to the attached receptor, IL-2Rα circulates in a soluble form (sIL-2Rα) high levels
of which have been associated with autoimmune diseases and coronary artery
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disease [93], suggesting an important role for T cells in general and possibly Treg
cells in particular.
Other types of T cells including T effector memory (TEM) cells, CD8+ T
cells, and natural killer T (NKT) cells play a role in atherosclerosis, although these
cell types have not been investigated as thoroughly as the other T cell types.
Murine studies showed that circulating TEM levels were positively correlated with
the extent of artheosclerotic lesions [94]. CD8+ cytotoxic T cells are less prevalent
in human lesions than CD4+ T cells and their impact on atherosclerotic
development, while minor, is still pro-inflammatory. CD8+ T cells induce
macrophages through the secretion of IFN-γ. Their presence in both human and
murine lesions has been noted for many years [95] and advanced lesions seem to
have a high concentration of cytotoxic T cells [96]. NKT cells are a minute subset
of T cells involved in self and non-self-recognition. These cells secrete numerous
cytokines including IL-4, IL-10, IL-13, IL-21, IFNγ, and TNFα. Their proatherogenic role has been studied and confirmed in murine models, additionally,
NKT cells have been detected in human plaques [97, 98].
Much like T cells, the impact of B cells on the development of
atherosclerosis is also complicated and has not been studied extensively. The work
of Caligiuri et al. in mice provided the first evidence of B cell involvement in
plaque development showing that the transfer of B cells, taken from the spleen, to
ApoE knockout mice conferred atherosclerotic protection [99] and these mice were
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found to have fewer CD4+ T cells suggesting that interactions between B cells and
T cells impact immune activity. More recent investigations have shown that B cell
depleted ApoE-/- and Ldlr-/- mice have significantly reduced plaques compared to
non B cell depleted mice [100, 101], suggesting B cells promote atherosclerosis.
This apparent contradiction in the role of B cells in atherosclerosis may be due to
the different roles of unique subsets. B2 cells which constitute the majority of B
cells and are derived from the bone marrow have an as yet undefined role in
atherosclerosis. B1a cells, mainly found in the pleural and peritoneal cavities, seem
to be atheroprotective [102].
The Role of Population Science in the Study of Atherosclerosis and
CVD.
Numerous epidemiology studies have provided much insight into risk
factors for CVD. These studies have also established risk assessment algorithms
that help to identify those persons who would benefit most from risk factor
interventions. In the early 1880’s [103] the lack of data on CVD had already been
recognized, but it took until 1934 for a conference to be convened to discuss CVD
in the population and to further describe the occurrence of atherosclerotic lesion
across cultures, geography, socioeconomic status and occupations [104]. The
1940’s saw the first attempts at using epidemiology as a tool to identify risk factors
and reduce the incidence of CVD. The first prospective study of heart disease was
initiated in 1947 by Ancel Keys and colleagues when they followed 281 middle
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aged men in Minnesota for 15 years [105] and found that there was a statistically
significant relationship between elevated serum cholesterol and coronary heart
disease. Keys followed up this work with the Seven Countries Study, one of the
pioneering epidemiologic studies of heart disease, during the mid to late 1950’s.
The Seven Countries Study was designed to examine the variability of heart disease
in populations in relation to the fat composition of the diet and the serum
cholesterol levels. Over twelve thousand men age 40 to 59, without evidence of
clinical CVD were recruited from the United States, Finland, Yugoslavia, the
Netherlands, Italy, Greece and Japan in this a cross cultural, prospective study [106,
107]. A 1970 paper from the Seven countries Study showed that diets high in
saturated fat lead to heart disease and that this association is mediated by serum
cholesterol [108]. With evidence that both saturated fatty acid intake and high levels
of serum cholesterol were strongly associated with risk of heart disease, the Seven
Countries Study had a large impact on the prevention of heart disease, and became a
model for using population science to identify risk factors and underlying
pathophysiologic mechanisms.
Important NHLBI-Funded Cohort Studies.
The Framingham Heart Study (FHS), begun in 1948, is another pioneering
epidemiology study [109]. The original cohort of 5,209 participants aged 30 – 62
years old from Framingham, MA received an extensive medical history, a
comprehensive physical exam, and numerous laboratory measurements including
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serum cholesterol and phospholipid and glucose levels [110]. In 1957, results from
FHS showed age- and sex-related differences in CHD, and demonstrated that high
blood pressure, elevated serum cholesterol levels, and being overweight were
predictors of heart disease [111]. The results from FHS contributed to the
identification of many factors associated with an increased risk of heart disease.
Cigarette smoking, hypertension, and elevated serum cholesterol were all
documented as being “risk factors”; a term coined by William B. Kannel, the
director of FHS [107]. The success of FHS lead to other observational studies in
CVD including the ARIC (Atherosclerosis Risk in Communities) study, the
CARDIA (Coronary Artery Risk Development in Young Adults) study, the CHS
(Cardiovascular Health Study), and the MESA (Multiethnic Study of
Atherosclerosis) [109] . While our laboratory has worked within all of these studies,
we have focused predominantly on CHS and MESA.
While CARDIA focuses on younger adults and the progression of risk
factors, and ARIC focuses on risk in the middle aged, CHS is a longitudinal cohort
study of 5888 participants with the main objectives of identifying risk factors for
coronary heart disease and stroke in the elderly [112]. Recruitment began in 1989
at four field centers for participants aged 65 years and older. CHS was the first
large scale, epidemiological study to focus on an older population. In addition to a
comprehensive physical exam, the baseline exam also included measures of
subclinical CVD such as intimal-medial carotid artery wall thickness by ultrasound,
electrocardiogram abnormalities, ankle brachial blood pressure index, and cardiac
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motion abnormalities by echocardiogram [107], as well as obtaining blood for fluid
biomarkers and DNA samples for genetic studies. Since the study’s inception, CHS
researchers have reported on cardiovascular morbidity [113], associated risk factors
for mortality [114], and associations among established and novel risk
factors/biomarkers and blood pressure and subclinical CVD [115] in an older
population.
MESA began in 2000 with the goal of understanding differences among
ethnic groups in both the prevalence and outcomes of subclinical atherosclerosis
[107, 116]. A population based cohort of 6814 men and women between the ages
of 45 and 84 years was recruited at six field centers; the only major exclusions
criterion was prior clinical CVD. The ethnic composition of the cohort is
approximately 38% European American, 28% African American, 23% Hispanic,
and 11% Asian [116]. The baseline exam for the participants was extensive.
Baseline measurements included coronary calcium using computed tomography,
ventricular mass and function using cardiac magnetic resonance imaging, flowmediated brachial artery endothelial vasodilation, carotid artery intimal medial wall
thickness (cIMT) and distensibility using ultrasonography, peripheral vascular
disease estimated by ankle and brachial blood pressures, and cardiac function by
electrocardiography. Other assessments included microalbuminuria, standard CVD
risk factors, sociodemographic factors, life habits, and psychosocial factors. Blood
samples were assayed for putative biochemical risk factors and also stored for use
in later studies. DNA was extracted and peripheral blood mononuclear cells were
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cryopreserved for genetic studies. Measurement of selected subclinical CVD
indicators and risk factors have been repeated at four subsequent exams with a sixth
exam currently ongoing. Participants are being followed for identification and
characterization of CVD events, including acute myocardial infarction and other
coronary heart disease, stroke, peripheral vascular disease, and congestive heart
failure; therapeutic interventions for CVD; and mortality [116]. MESA added to
literature by being the first major study to assess subclinical CVD by using cardiac
MRI [117] and by being the first to show coronary artery calcium differences
among ethnicities as well as its association with coronary events [118, 119]. One of
the largest contributions that these epidemiology studies have made to the
understanding of CVD and the reduction of CVD is the development of risk
markers.
Molecular Epidemiology.
A main objective of these CVD epidemiology studies has been (and
remains) the detection of persons of high-risk through screening measures. At first,
research focused on tests having the greatest predictive power. However, these tests
were associated with very small, high-risk populations. Toward the 1970’s, the
approach for a reduction of CVD began to focus on prevention and control
programs centered on the entire population. In essence, CVD became a public
health issue. Rose’s 1981 publication defined the ‘mass strategy’ of prevention,
which brought the focus of CVD reduction to not only those high risk patients, but
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all members of the population [120]. The FHS helped to identify blood pressure,
cigarette smoking, blood lipids and adiposity as conventional risk factors for CVD
and a risk prediction equation was developed. The Framingham risk score,
calculated using age, sex, systolic blood pressure (treated or untreated status), total
cholesterol, HDL cholesterol, smoking behavior, and diabetes status, proved to be a
reliable measure of CVD potential not only in European American men and women
but also for African American men and women [121, 122]. While a good predictor
of CHD risk, these conventional risk factors only explained part of the risk [123,
124]. Researchers have looked to novel biomarkers, independently associated with
CHD, to explain not only the remaining risk, but also to provide insight into the
biology of CHD development. A number of these biomarkers are associated with
the inflammatory response including IL-6, C-reactive protein (CRP), and fibrinogen
among others [124-126]. Mouse studies and population studies both linked these
inflammation markers to CHD development, progression and outcomes, while
adding valuable knowledge of CHD biology and pathology. While they do not
significantly improve risk score prediction models in the general population,
recommendations suggest usefulness of CRP in certain settings [127]. Yeboah et
al. compared novel risk markers in MESA and showed that including coronary
artery calcium in the risk score improved risk classification for people previously
classified as at intermediate risk by the Framingham score [128]. A novel, easily
measured biomarker proven both a reliable diagnostic and prognostic tool would be
beneficial in clinical practice and in treatment. One area where these biomarkers
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may prove useful is in specific subpopulations such as the elderly [126]. ‘If the
markers reflect different aspects of the disease process at different points in the
natural history of the disease, this has implications for the interpretation of marker
levels and the timing of future events.’ [126]
Genetic Epidemiology.
With the advent of genotyping, the quest for biomarkers, which elucidate the
biological pathways of CHD and which present targets for intervention, took on a
genetic focus. For decades, scientists have recognized that there is a link between a
family history of CHD and an increased risk of heart disease. In 2004, Lloyd-Jones
et al. showed that when a parent has a history of atherosclerotic CVD, the child will
have ~3-fold increased risk of CVD [129]. Beginning with candidate gene studies,
moving to genome wide association studies (GWAS) and now whole genome
sequencing, researchers are examining associations between genotype and
outcomes, genotype and risk factors, and genotype and biomarkers. Some types of
CVD have a single causal gene, which has a large effect on a particular phenotype.
One example of this was identified in 1985 by Lehrman et al. when they found a 5
kilo base deletion in the low-density lipoprotein receptor gene of a patient with a
family history of hypercholesterolemia [130]. However, most CVD risk factors
seem to result from complex interactions between numerous genes and non-genetic
factors. The completion of the Human Genome Project in 2003 [131, 132], followed
by the completion of the HapMap Project in 2005 [133, 134], gave scientists the
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ability to analyze common genetic variants for their association with CVD
phenotypes with a near complete catalog of genes and new technologies. GWAS
genotyped common variants, mostly single nucleotide polymorphisms (SNPs)
throughout the genome and analyzed these for association with CVD events, risk
factors or biomarkers. GWAS results reported in 2007 identified an association
between heart disease and SNPs located in the p21 region of chromosome 9 [135137]. A recent search for results in the GWAS catalogue [138] with the search term
‘cardiovascular disease’ reveals that there have been 324 publications citing 2224
genetic associations with 183 traits related to CVD. Since GWAS uses tag-SNPs
which “tag” functional SNPs scattered across the genome, most of these associated
variants are in non-coding regions of the genome and are not causal. However, the
associations may point to casual areas of the genome, which need further
investigation. Mapping studies and expression profiling as well as work in human
cell lines and animal models are necessary to identify the functional variant.
The Molecular Epidemiology of Innate and Adaptive Immunity &
CVD.
Through many decades of observation and experimentation, it has become
clear that atherosclerosis is a complex disease process involving cellular
proliferation, biochemical processes, genetics and environmental influences.
While, as noted above, there is ample basic research to support the critical role of
innate and adaptive immunity in atherosclerosis and CVD, there is only a small
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body of work that directly addresses these roles through blood measures in
epidemiologic cohorts. Regarding CD4+ T helper cells, Tracy et al. have shown a
strong, independent association of Th1 bias with both coronary calcification and
cIMT [139]. They went on to show that the single greatest association of an
environmental variable with Th1 bias involved cytomegalovirus response. Work by
Engelbertsen et al. in the Malmo Diet and Cancer Study showed an association
between T cells and atherosclerosis; an analysis of seven hundred participants found
that a high number of Th2 cells was associated with a decreased mean cIMT [77].
This was confirmed by Tracy et al., who showed that Th2 cells were associated
with lower cIMT in MESA [139]. Increased numbers of Th2 cells were associated
with a reduced risk of myocardial infraction in women and serum IL-4 was
associated with a reduced risk of CVD in both men and women [78]. Regarding the
activation of adaptive immunity as assessed by measuring Effector/Memory cells
vs. Naïve cells, Ammirati et al. analyzed data from over 400 patients and found that
TEM cells were strongly related to increased IMT. Olson et al. analyzed TEM levels
from more than 900 participants in the Multi-Ethnic Study of Atherosclerosis and
found that TEM levels were positively associated with cIMT and the inflammatory
cytokine IL-6 [41].
An analysis of the Framingham Heart Study which combined genome-wide
association studies, gene expression and phenotypes found that B cells contributed
to coronary artery disease [140]. This work linked phenotypic observations with
molecular networks and genetic results supporting the theory that B cells are pro26

atherogenic and substantiating murine results that B cells are involved in lipid
dysregulation [141].
Research Reported in this Dissertation.
The research reported here studied aspects of both the innate and the
adaptive immune system in CVD from both molecular and genetic epidemiological
standpoints in an effort to increase our understanding of the CVD disease process.
‘Plasma Levels of Soluble Interleukin-2 Receptor α Associations with Clinical
Cardiovascular Events and Genome-Wide Association Scan’ examines the
relationship of cell-mediated immunity to CVD through the association of soluble
interleukin-2 receptor α (sIL-2Rα; a biomarker of T cell activation) with CVD risk
factors, CVD events and with common genetic polymorphisms. Both interleukin-2
and interleukin-2 receptor play significant roles in the proliferation and
differentiation of T cells.
The second paper ‘Circulating Soluble CD163, Genetic Associations, and Risk of
Cardiovascular Disease and All-Cause Mortality in Older Persons: the
Cardiovascular Health Study’, examines the innate immune systems through the
association of soluble CD163 (sCD163), a marker for M2 macrophages, with CVD
risk factors, outcomes, and common polymorphisms.
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ABSTRACT

Objective: Interleukin-2 receptor subunit alpha (IL-2Rα) regulates lymphocyte
activation, which plays an important role in atherosclerosis. Associations between
soluble IL-2Rα and cardiovascular disease (CVD) have not been widely studied and
little is known about the genetic determinants of sIL-2Rα levels. Approach and
Results: We measured baseline levels of sIL-2Rα in 4408 European-American (EA)
and 766 African-American (AA) adults from the Cardiovascular Health Study (CHS)
and examined associations with baseline CVD risk factors, subclinical CVD and
incident CVD events. We also performed a genome-wide association study (GWAS)
for sIL-2Rα in CHS (2964 EAs and 683 AAs) and further combined CHS EA results
with those from two other EA cohorts in a meta-analysis (N=4464 EAs). In age, sexand race- adjusted models, sIL-2Rα was positively associated with current smoking,
type 2 diabetes, hypertension, insulin, waist circumference, C-reactive protein,
interleukin-6, fibrinogen, internal carotid wall thickness, all-cause mortality, CVD
mortality, and incident CVD, stroke and heart failure. When adjusted for baseline
CVD risk factors and subclinical CVD, associations with all- cause mortality, CVD
mortality and heart failure remained significant in both EAs and AAs. In the EA
GWAS analysis, we observed 52 single nucleotide polymorphisms (SNPs) in the
chromosome 10p15-14 region, which contains IL2RA, IL15RA and RMB17, that reached
genome-wide significance (p<5x10-8). The most significant SNP was rs7911500
(p=1.31x10-75). The EA meta-analysis results were highly consistent with CHS-only
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results. No SNPs reached statistical significance in the AAs. Conclusions: These
results support a role for sIL-2Rα in atherosclerosis and provide evidence for multiple
associated SNPs at chromosome 10p15-14.

Abbreviations
Interleukin-2 (IL-2)
Soluble interleukin-2 receptor alpha (sIL-2Rα)
Cardiovascular disease (CVD)
European-American (EA)
African-American (AA)
Cardiovascular Health Study (CHS)
Genome-wide association study (GWAS)
Single nucleotide polymorphism (SNP)
Health, Aging and Body Composition Study (Health ABC)
Quality control (QC)
Intima media thickness (IMT)
Coronary heart disease (CHD)
Congestive heart failure (CHF)
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Interleukin-6 (IL-6)
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INTRODUCTION
Interleukin (IL)-2 and IL-2 receptor (IL-2R) signaling play an important role in
regulating both tolerance and immunity. IL-2 is a T cell growth factor, inducing the
proliferation and differentiation of antigen-activated T cells1,2, and is particularly
important in the development of regulatory T cells in the thymus3. The IL-2R is a
trimeric receptor composed of the IL-2Rα subunit (CD25), the IL-2Rβ subunit
(CD122), and the IL-2γc subunit (CD132). IL-2Rα is specific for IL-2R, while IL2Rβ and IL-2Rγc are shared components of other cytokine receptors (e.g., IL-15)4,5.
sIL-2Rα results from the proteolytic cleavage of IL-2Rα at the cell surface by a
membrane metalloproteinase (ectodomain shedding)6; which is encoded by IL2RA on
human chromosome 10. The function of sIL-2Rα has not been fully elucidated.
Since the sIL-2Rα has IL-2 binding kinetics similar to the membrane form, sIL-2Rα
may serve to mitigate the immune responses by binding and sequestering IL-27.
High plasma levels of sIL-2Rα have been associated with autoimmune diseases
including Crohn’s disease8, rheumatoid arthritis9, and multiple sclerosis10 and
higher levels have been observed in patients with coronary artery disease11. Murine
models have shown that IL-2 increases regulatory T cell numbers in atherosclerotic
plaques and also reduces the size of those plaques12. When the IL-2 receptor is
blocked in the same model, the plaque reduction is negated.
Despite its potential importance in the immune system and cardiovascular disease
(CVD), sIL-2Rα has not been widely investigated in large prospective population48

based studies of CVD. A 2003 study in the Health, Aging and Body Composition
(Health ABC) study did not result in evidence for a significant association between
sIL-2Rα and CVD; however, sIL-2Rα measurements were only available in a subset of
N=499 participants. In addition, little is known about the genetic determinants for sIL2Rα levels. While genome-wide association studies (GWAS) have identified single
nucleotide polymorphisms (SNPs) in the IL-2RA gene for several autoimmune
diseases10, there have been no published reports for GWAS of serum levels of sIL2Rα.
In the current study, we examined sIL-2Rα levels in the Cardiovascular Health
Study (CHS), a cohort of older adults with follow-up for incident clinical CVD and
mortality for up to 20 years. We examined the relationships between sIL-2Rα at
baseline and incident events as well as cross-sectionally with other CVD and
inflammatory markers (fibrinogen, C-reactive protein [CRP], and IL-6). We then
conducted a GWAS and region-specific conditional analyses to identify genetic variants
associated with sIL-2Rα levels. Finally, we performed a GWAS meta-analysis,
including results from two additional studies: the Health ABC study and the MultiEthnic Study of Atherosclerosis (MESA), to increase our power to detect associated
variants not detected in CHS alone.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
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RESULTS
Associations between sIL2Rα and baseline CVD risk factors and other
inflammation biomarkers
The characteristics of the 5174 CHS participants with sIL-2Rα measurements at the
baseline exam are summarized in Table 1, and Spearman correlation coefficients for
sIL-2Ra with each continuous CVD risk factor and IMT are given in Supplemental
Table 1. sIL-2Rα levels were on average higher in older individuals, higher in men,
and higher in EAs. At baseline, mean sIL-2Rα levels were 1146.4 pg/mL (standard
deviation (SD)=507.5 pg/mL) and 1101.6 pg/mL (SD=556.4 pg/mL) in EA men and
women, respectively; and 873.1 pg/mL (SD=505.5 pg/mL) and 910.9 pg/mL
(SD=581.2 pg/mL) in AA men and women, respectively. In age-, race- and sexadjusted models sIL-2Rα was additionally associated with current smoking, type 2
diabetes, hypertension, fasting insulin, waist circumference, CRP, IL-6, fibrinogen,
and internal carotid wall IMT and negatively associated with LDL and high density
lipoprotein (HDL) cholesterol. After further adjustment, sIL2Ra levels remained
associated with age, race, smoking, hypertension, lipids, and inflammation.
Incident events analysis
We performed survival analysis in 4406 EAs and 768 AAs. There were
2985(EA)/451(AA) all- cause deaths; including 1202/186 cases of cardiovascular
mortality. There were 1234/195 incident cases of CHD, 762/117 incident strokes, and
1246/199 incident cases of heart failure (fatal and non-fatal events). When minimally
adjusted for age, sex, race, and study site, baseline sIL-2Rα was significantly
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associated with increased risk for all outcomes in both EAs and AAs (Table 2).
Results were slight attenuated in EAs after additional adjustment for baseline risk
factors except for stroke, and not attenuated at all in AAs. When further adjustment
was made for inflammation status and measures of subclinical CVD, all-cause
mortality and heart failure remained significant for both the EAs and AAs;
cardiovascular mortality remained significant only for EAs; and stroke remained
significant only for AAs. Effect estimates were mostly similar between EAs and
AAs (sIL-2Rα as a continuous predictor). In analyses where sIL-2Rα was modeled in
quartiles, the risk of increased sIL-2Rα for stroke in AAs appears to be driven by the
highest quartile of sIL-2Rα as compared to a more graded effect in EAs. We
estimated a 63%(EA)/67%(AA) increased risk for all-cause mortality, and a
57%/71% increased risk of heart failure for individuals in the fourth quartile versus
those in the first quartile, after adjustment for both established CVD risk factors,
inflammation biomarkers and subclinical measures of CVD. For cardiovascular
mortality, this estimated increased risk was 64% in EAs and not significant in AAs;
and 28% in EAs and 130% in AAs for stroke.
Genome-wide association study of sIL-2Rα in CHS EA and AA
We conducted a race-stratified GWAS in 2964 EAs and 683 AAs from CHS that had
both sIL-2Rα measurement and GWAS data available. A total of 52 SNPs in the
chromosome 10p15- p14 region (containing IL2RA, IL15RA, and RBM17) reached
genomewide significance (p<5x10-8) in the EA analysis. The most significant SNP
was rs7911500 (p=1.31x10-75), which is located between IL2RA and IL15RA. No
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other regions reached genome-wide significance in the EA analysis. No SNPs reached
genome-wide significance in the AA analysis. The top findings in AAs were for an
intergenic SNP between BRE and FOSL2 on chromosome 2 (rs7602568, p=5.8x10-6)
and an intronic SNP in ADK (rs12220238, p=8.3x10-6), nearly 70Mb from IL2RA on
chromosome 10. IL2RA SNP rs7911500 (p=0.52) demonstrated no evidence for
association in AAs, though the minor allele frequency for this variant in AAs was only
2.5% (compared to 13.4% in EAs). Several chromosome 10p15-p14 SNPs between
IL15RA and IL2RA (lead SNP rs8177607, p=3.2x10-4) provided nominal evidence for
an association in AAs. rs8177607 showed no evidence for association in EAs
(p=0.65).
Conditional and multiple variant analysis of IL2RA region in CHS EA
In the CHS EAs, as described in Methods, we performed an iterative, forwardselection conditional analysis of the chromosome 10p14-15 region (approximately a
200 Kb span), beginning with conditioning on the rs7911500 SNP (Figure 1). The
order of additional SNP conditioning was rs791590 (pcond=7.0x10-35; an intronic
SNP in IL2RA), rs8177757 (pcond=2.3x10-10; located between IL15RA and IL2RA),
rs10905716 (pcond=3.3x10-9; located between IL2RA and RBM17), and finally
rs7924005 (pcond=4.4x10-10; located in LOC101928080 downstream from RBM17).
There was still nominal evidence for further association of SNPs in the region after
adjusting for these five, although none reached genome-wide significance. The
multiple variant penalized regression method LLARRMA identified six SNPs
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(Resample Model Inclusion Probability (RMIP) > 0.8; namely, rs2104286 (RMIP
=1.00), rs7924005 (RMIP=0.995), rs10905716 (RMIP=0.995), rs4749955
(RMIP=0.911), rs11256497 (RMIP=0.899), and rs7898880 (RMIP=0.871)) that were
consistently associated with sIL-2Rα levels across alternative resamplings of the data.
Our top SNP in our initial GWAS, rs7911500 (RMIP = 0.002) was not predicted to be
important in the multi-SNP LLARRMA model. However, LLARRMA did include the
top variant, rs791590 (RMIP = 0.592), from the conditional analysis after conditioning
on rs7911500, more often than not in the final multi-SNP model across different
resamplings of the data.
The five index SNPs identified in the conditional analysis, in total explain
approximately 14% of the variation in sIL-2Rα levels after adjusting for age, sex and
PCs to account for population admixture. When we further examined these five SNPs
individually for association wi th i n c i d e n t cardiovascular events in CHS, none of
them was significant. We also observed no evidence for an association between a
genetic risk score (equal to the sum of the alleles individually associated with
increased sIL-2Rα for these five SNPs ) and clinical events.
Meta-analysis of CHS, MESA and Health ABC EA
We conducted a meta-analysis combining GWAS results for CHS (N=2964), MESA
(N=714) and Health ABC (N=786) EA participants to increase power to detect loci
potentially missed in the CHS-only analysis. Meta-analysis results were highly
consistent with those observed in the CHS-only analysis, where only variants in the
chromosome 10p15-p14 region (IL15RA/IL2RA/ RBM17) reached statistical
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significance (Figure 2). A total of 95 SNPs in this region were significant in the metaanalysis, and the most significant SNP remained rs7911500 (p = 1.1 x10-100).
We assessed the evidence for association between sIL2r and 1093 variants
reported as significant in prior GWAS studies, according to the NHGRI GWAS
catalogue (https://www.genome.gov) for the traits listed in Table 1. Only our top two
SNPs, rs7911500 and rs12722606, which were previously reported to be significantly
associated with an inflammatory phenotype based on the IL-6 – CRP pattern, were
statistically significant with the sIL2rα levels in this candidate variant analysis after
Bonferroni correction for 1093 test (p<4.6x10-5). Additionally, we searched the
CARDIoGRAM+C4D database containing data from multiple GWAS (63,746 case
and 130681 controls) combined to determine variants associated with coronary artery
disease and myocardial infarction (http://www.cardiogramplusc4d.org14,15,16). No
significant associations (all p>0.05) between our SNPs and CVD were identified.
DISCUSSION
We report the first large-scale assessment of sIL-2Rα for association with CVD related
traits and events in a prospective cohort and the first GWAS for SNPs associated with
sIL-2Rα levels. The major findings from this study are: A) sIL-2Rα levels are
associated with a number of established CVD risk factors and carotid IMT, a measure
of subclinical CVD. B) Plasma sIL-2Rα predicted all-cause mortality and
cardiovascular mortality independently of CVD risk factors and baseline subclinical
CVD. C) In CHS alone (N=2961) we identified 52 SNPs in the chromosome 10p15p14 region with genome-wide significance for association with plasma sIL-2Rα levels;
54

most significant was rs7911500, intergenic to IL15RA and IL2RA. D) Conditional
analysis indicated that there are multiple SNPs independently associated in this region;
the five most significant loci, in total explain approximately 14% of the variation in
plasma sIL-2Rα levels in CHS EAs. E) Combining results from EAs in CHS and two
additional cohort studies, MESA and Health ABC (n=4464), did not result in any
additional significantly associated loci. F) We did not identify any significant
associations in the CHS AAs, although we did observe nominal evidence for
association in the IL15RA/IL2RA region. G) There was no evidence that sIL-2Rαassociated SNPs were associated with incident clinical events in CHS; we also
observed no evidence of association with coronary artery disease and myocardial
infarction in a search of the CARDIoGRAM+C4D database results for these
SNPs14,15,16.
Activated T lymphocytes play an important role in atherosclerosis promoting
chemokine secretion, inflammation, and eventually, the formation of atherosclerotic
plaques. IL-2, produced by T helper 1 cells, has been found in plaques and contributes
to the development of atherosclerosis by its interaction with the IL-2 receptor
increasing lymphocyte activation13. IL-2 stimulates the synthesis of interferon gamma
thereby promoting an increased immune response and atherosclerotic progression.
However, IL-2 also promotes regulatory T cells, and may have an atheroprotective
role as well12.
While sIL-2Rα is a strong biological candidate for use as a biomarker for CVD
morbidity and mortality, epidemiologic studies have been limited. Analysis in the
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Health ABC study did not identify evidence for an association between sIL-2Rα and
either subclinical (p=0.27) or clinical CVD (p=0.27), but measured sIL-2Rα levels
were only available on a subset of 499 of the 3045 participants with incident event
data. Although it was not statistically significant, median sIL-2Rα level was slightly
higher in those with incident clinical CVD as compared to those with no CVD (1.4
mg/mL versus 1.2 mg/mL)14. Investigators from another study of 286 Japanese
patients that underwent angiography (167 coronary artery disease [CAD] cases and 119
controls) reported a significant positive association of sIL-2Rα and cross-sectional
CAD case status based on extreme quartiles of sIL-2Rα (p=0.005 for minimally
adjusted model and p=0.035 for model with additional adjustment for CVD risk
factors)11. The current study represents the first well-powered effort examining sIL2Rα level prospectively with clinical CVD events and all-cause mortality. We
observed statistically significant evidence for all incident events examined (all-cause
mortality, CVD mortality, incident CHD, stroke and heart failure) in minimally
adjusted models, and for all-cause mortality, CVD mortality and incident heart failure
in fully adjusted models. We found sIL-2Rα levels to be significantly associated with
carotid intima-media thickness in the minimally adjusted model; although this did not
remain significant when other cardiovascular risk factors were added to the model.
Fifty-two chromosome 10p15-p14 SNPs were significantly associated (p<5x10-8)
with plasma sIL-2Rα levels in CHS EAs; no other regions reached genome-wide
significance. The most significant SNP, rs7911500, was located between IL15RA and
IL2RA. Iterative conditional analyses identified a total of five significant “independent”
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SNPs across the region. LLARRMA identified six SNPs that were consistently associated
with sIL-2Rα levels across alternative resamplings of the data. Both iterative conditional
analyses and LLARRMA provide compelling evidence for the existence of multiple
important causal variants in the region, though they did not agree with respect to the
importance of our most significant SNP, rs7911500. Higher density genotype data,
including both common haplotype-tagging variants and less-common putative functional
variants, will be necessary to fine map the association signals in this region. Two of our
significant SNPs in the region, rs2104286 (p=4.9x10-59; the top SNP identified by
LLARRMA) and rs11594656 (p=1.5x10-41), have been shown to function in
transcription factor binding. These SNPs have also been reported to be associated with
sIL2Rα levels and type 1 diabetes and multiple sclerosis15, 16.
No regions reached genome-wide significance in the smaller cohort of CHS
AAs. Nominal evidence for association in AAs was detected between IL15RA and
IL2RA (best result: rs8177607, p=3.2x10-4). The lead SNP in EAs, rs7911500, was
less polymorphic in AAs and demonstrated no evidence for association. Similarly, no
evidence for association was found for rs791590 (p=0.31) or rs10905716 (p=0.43),
two significant variants in EAs in the conditional analyses. The two other significant
SNPs in the conditional analyses, rs8177757 and rs7924005, were not successfully
imputed in the AAs. The difference in findings between EAs and AAs could suggest
different risk variants in the two populations, be reflective of different LD structures in
the region that mask common underlying causal variants, or be the result of lower
power in AAs. There are strong allele frequency differences between the two
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populations for many of the EA SNPs in the region (see Supplemental Table 2 for
frequencies in HapMap CEU and YRI populations) and the AA sample size is
considerably smaller than for EAs.
Interestingly, the top SNP from LLARRMA, rs2104286, in EAs was nominally
significant in AAs (p=0.011) despite the lower estimated frequency of the minor allele
in AAs (MAF=0.065) compared to EAs (MAF=0.27). The effect estimates for the
SNP were similar in AAs (β= -0.17) and EAs β=-0.15), where carriers of the minor
allele were predicted to have lower sIL-2Rα levels.
Elevated sIL-2Rα levels have been shown to be associated with a number of
autoimmune diseases and may predict a relapse of those diseases7. We found a
number of IL2RA SNPs previously associated with autoimmune-related diseases to be
significantly associated with sIL-2Rα levels. A number of our significant SNPs have
also been observed to be associated in GWAS, fine mapping studies and SNP specific
genotyping studies for autoimmune diseases including Graves’ disease (rs11594656,
Odds Ratio (OR)=1.54, p=0.0053)17 , vitiligo (rs706779 OR=1.27, p=3X10-9)18,
Crohn’s disease (rs12722489, OR=1.11, p=3X10-9) 19 , type 1 diabetes (rs7090530,
OR=1.23, p=0.003)20 and multiple sclerosis (rs2104286, OR=0.81, p=0.017)20 . Our
two most significant SNPs, rs7911500 and rs12722605, were found to be
significantly associated with an inflammatory phenotype derived from the highsensitivity CRP-interleukin-6 (IL-6) pattern in a G W A S o f the Genetics of Lipid
Lowering Drugs and Diet Network (p=5x10-9 and p=5x10-8)21. The nature of this
association is uncertain; it is possible that these variants or others in linkage
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disequilibrium with them are directly increasing the sIL-2Rα levels which in turn
results in downstream increases in both IL-6 and CRP.
There are several limitations in the current study which should be noted. We only
analyzed common variants; rare polymorphisms may account for much of the
variability in the sIL-2Rα levels. Also, we had weak statistical power to detect
associations in AAs. Finally, our study was focused on older adults and the results
may not be generalizable to other populations.
Our findings suggest that serum sIL-2Rα, a surrogate marker of T lymphocyte
activation, may be a valuable novel biomarker for all-cause mortality, cardiovascular
morality, stroke and heart failure in older adults. Additional studies are needed to
assess whether sIL-2Rα levels predict mortality in younger populations. Also, further
studies are needed a) to identify the causal variants in the chromosomal region
harboring IL15RA and IL2RA influencing sIL-2rα, b) to provide very large and multiethnic samples to identify additional genetic loci for this trait, and c) to determine the
complex biology of the genetic control of IL-2/IL-2R interactions with respect to
regulatory T cell promotion and pro-inflammatory cytokine production.
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Significance

This study found that sIL-2Rα, a regulator of white blood cells, is associated with a
number of cardiovascular disease risk factors, as well as with all-cause mortality,
cardiovascular disease mortality, and heart failure in the Cardiovascular Health
Study. Analysis of genetic variants in European Americans found a number of
variants in the chromosome 10 region containing the genes IL2RA, IL15RA, and
RMB17 to be significantly associated with sIL-2Rα. These results provide support for
a role of sIL-2Rα in atherosclerosis and cardiovascular disease.
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Table 1: Associations between Soluble IL-2Rα and Other Cardiovascular Risk Factors and Atherosclerosis at the CHS Baseline Examination
Each variable was examined for association with sIL-2Ra in a separate model, adjusting for the variables listed in each model; the exception is
that a variable is not adjusted for itself when it is the variable being tested. β for all measures except sex, race, diabetes, and hypertension are for a
1–SD change in the predictor; sIL-2Rα ln-transformed p values;
*P<0.01; **P<0.001; ***P<0.0001.
Model A: adjusted for age, race, and sex.
Model B: adjusted for age, race, sex, smoking, diabetes mellitus, hypertension, systolic blood pressure, and BMI.
Model C: adjusted for age, race, sex, smoking, diabetes mellitus, hypertension, systolic blood pressure, BMI, LDL cholesterol, HDL cholesterol, Creactive protein, interleukin-6, and fibrinogen.

Baseline Characteristics (Mean±SD or %)

Model
A
β±SE

Model
B β±SE

Model
C β±SE
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Age, y (5.6)

0.074±0.005***

0.078±0.006***

0.067±0.006***

Female sex (57.2 %)

-0.029±0.011*

-0.031±0.011*

0.017±0.012

Black race (14.8%)

-0.120±0.007***

-0.133±0.008***

-0.134±0.008***

Current smoking (54.0 %)

0.100±0.164***

0.108±0.017***

0.079±0.017***

Type 2 diabetes (16.2 %)

0.056±0.014**

0.042±0.015**

-0.002±0.015

Hypertension (44.5 %)

0.042±0.006***

0.046±0.007***

0.030±0.007***

Systolic blood pressure, mm Hg (136.6±21.8)

0.013±0.005

-0.011±0.026

0.003±0.007

LDL cholesterol, mg/dL (129.8±35.6)

-0.030±0.005***

-0.030±0.005***

-0.032±0.007***

HDL cholesterol, mg/dL (54.2±15.7)

-0.055±0.006***

-0.050±0.006***

-0.046±0.006***

Triglycerides, mg/dL (139.8±76.7)

0.007±0.005

-0.002±0.006

-0.025±0.008*

Glucose, mg/dL (111.1±35.9)

0.013±0.005

-0.009±0.008

-0.013±0.007

Insulin, IU/mL (17.4±27.4)

0.023±0.005***

0.017±0.005*

0.011±0.005

BMI, kg/m2 (26.6±4.7)

0.009±0.006

0.005±.006

-0.016±0.006*

Waist circumference, cm (94.4±13.1)

0.014±0.005*

0.016±0.010

0.003±0.010

C-reactive protein, mg/L (4.8±8.0)

0.083±0.005***

0.080±0.005***

0.043±0.008***

Interleukin-6, pg/mL (2.2±1.8)

0.059±0.005***

0.051±0.005***

0.024±0.006***

Fibrinogen, mg/dL (323.8±67.3)

0.067±0.005***

0.063±0.054***

0.032±0.006***

Internal carotid wall thickness, mm (1.5±0.7)

0.027±0.006***

0.014±0.006

0.009±0.006
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Table 2: Hazard ratios (HR) between sIL-2Rα and incident events in CHS
A: European Americans
Model 1: Adjusted for age, sex, and study site
Model 2: Model 1 + smoking, diabetes, hypertension, SBP, LDL, baseline CVD
Model 3: Model 2 + C-reactive protein, interleukin-6, fibrinogen, carotid intima-media thickness
‡ Hazard ratios for a 1-SD unit increase in soluble IL-2R.
‡‡Hazard ratios comparing quartiles to first quartile of soluble IL-2R. P values; *p<0.05; **p<0.005;
***p<0.0001.

Model

All-Cause
Mortality
(n=2985 events)
HR (95%CI)

Cardiovascular
Mortality
(n=1202 events)
HR (95%CI)

Coronary
Heart Disease
(n=1234 events)
HR (95%CI)

Stroke
(n=762 events)
HR (95%CI)

Heart Failure
(n=1246 events)
HR (95%CI)
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Minimal‡ (1)

1.17 (1.14-1.19)***

1.16 (1.11-1.20)*** 1.11 (1.05-1.15)***

1.08 (1.01-1.14)*

1.16 (1.12-1.21)***

Multivariable
‡ (2)

1.16 (1.13-1.19)***

1.15 (1.10-1.20)*** 1.10 (1.05-1.15)***

1.06 (0.99-1.14)

1.17 (1.12-1.22)***

Subclinical
‡ (3)
2nd Q vs 1st Q
‡‡ (3)

1.14 (1.11-1.18)***

1.13 (1.07-1.19)***

1.05 (0.99-1.11)

1.03 (0.95-1.12)

1.14 (1.08-1.19)***

1.17 (1.04-1.32)*

1.19 (0.98-1.45)

1.16 (0.97-1.39)

1.46 (1.16-1.84)**

1.17 (0.97-1.40)

1.25 (1.11-1.41)***

1.38 (1.10-1.62)**

1.23 (1.03-1.46)*

1.38 (1.09-1.74)*

1.16 (0.97-1.40)

1.63 (1.45-1.83)***

1.64 (1.36-1.99)***

1.16 (0.97-1.402)

1.28(1.01-1.64)*

1.57 (1.31-1.88)***

3rd Q vs 1st Q
‡‡ (3)
4th Q vs 1st Q
‡‡ (3)

Table 2: Hazard ratios (HR) between sIL-2Rα and incident events in CHS
B: African Americans
Model 1: Adjusted for age, sex, and study site
Model 2: Model 1 + smoking, diabetes, hypertension, SBP, LDL, baseline CVD
Model 3: Model 2 + C-reactive protein, interleukin-6, fibrinogen, carotid intima-media thickness
‡ Hazard ratios for a 1-SD unit increase in soluble IL-2R.
‡‡Hazard ratios comparing quartiles to first quartile of soluble IL-2R. P values; *p<0.05; **p<0.005;
***p<0.0001.

All-Cause
Mortality
(n=451 events)
HR (95%CI)

Cardiovascular
Mortality
(n=186 events)
HR (95%CI)

Coronary
Heart Disease
(n=195 events)
HR (95%CI)

Stroke
(n=117 events)
HR (95%CI)

Heart Failure
(n=199 events)
HR (95%CI)

Minimal‡ (1)

1.17 (1.10-1.25)***

1.14 (1.02-1.28)*

1.15 (1.04-1.28)**

1.16 (1.02-1.33)*

1.18 (1.07-1.29)**

Multivariable
‡ (2)
Subclinical
‡ (3)
2nd Q vs 1st Q
‡‡ (3)
3rd Q vs 1st Q
‡‡ (3)
4th Q vs 1st Q

1.17 (1.04-1.26)***

1.15 (1.02-1.31)*

1.19 (1.06-1.33)**

1.21 (1.04-1.40)*

1.19 (1.07-1.32)**

1.16 (1.07-1.18)***

1.07 (0.89-1.29)

1.12 (0.96-1.31)

1.22 (1.06-1.41)*

1.21 (1.09-1.35)***

0.99 (0.76-1.29)

1.02 (0.67-1.55)

1.42 (0.98-2.06)

0.94 (0.55-1.61)

1.37 (0.93-2.01)

1.31 (0.99-1.73)

1.48 (0.94-2.23)

1.50 (0.99-2.29)

1.20 (0.67-2.14)

1.84 (1.23-2.77)**

1.67 (1.22-2.28)**

1.33 (0.79-2.25)

1.09 (0.61-1.94)

2.30 (1.34-3.95)**

1.71 (1.05-2.80)*

Model
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‡‡ (3)

Figure 1a: Conditional Analysis - CHS IL2sR alpha adjusted by rs7911500
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Figure 1b: Conditional Analysis - CHS IL2sR alpha adjusted by rs7911500 and rs791590

72

Figure 1c: Conditional Analysis - CHS IL2sR alpha adjusted by rs7911500, rs791590 and
rs8177757

73

Figure 1d: Conditional Analysis - CHS IL2sR alpha adjusted by rs7911500, rs791590,
rs8177757, and rs10905716
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Figure 1e: Conditional Analysis - CHS IL2sR alpha adjusted by rs7911500, rs791590,
rs8177757, rs10905716, and rs7924005
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Figure 2:

Meta Analysis of European Americans

76

Plasma Levels of Soluble Interleukin-2 Receptor α: Associations With Clinical
Cardiovascular Events and Genome-Wide Association Scan
Peter Durda, Jeremy Sabourin, Ethan M. Lange, Mike A. Nalls, Josyf C. Mychaleckyj, Nancy
Swords Jenny, Jin Li, Jeremy Walston, Tamara B. Harris, Bruce M. Psaty, William Valdar,
Yongmei Liu, Mary Cushman, Alex P. Reiner, Russell P. Tracy and Leslie A. Lange
Arterioscler Thromb Vasc Biol. 2015;35:2246-2253; originally published online August 20,
2015;
doi: 10.1161/ATVBAHA.115.305289
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272
Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://atvb.ahajournals.org/content/35/10/2246

Data Supplement (unedited) at:
http://atvb.ahajournals.org/content/suppl/2015/08/24/ATVBAHA.115.305289.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the
Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which
permission is being requested is located, click Request Permissions in the middle column of the Web page under
Services. Further information about this process is available in the Permissions and Rights Question and Answer
document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

f

i

b

b

ibi

l

77

h

b

d

l

l

i

li

METHODS Arterioscler Thromb Vasc Biol. 2015;35:2246-2253

Study samples
The Cardiovascular Health Study (CHS) is a prospective population-based cohort study
of men and women recruited at age 65 or older at baseline. The original cohort of 5201
participants was recruited between 1988 and 1989 at four field centers: Forsyth County,
NC; Sacramento County, CA; Washington County, MD; and Pittsburgh, PA. Between
1992 and 1993, an additional 687 mostly African-American (AA) participants were
recruited for a total cohort of 5888. The baseline examination for CHS participants
included a medical history, demographic and lifestyle history, physical exam, fasting
blood collection and an assessment of vascular disease by carotid ultrasound and anklebrachial index.
The Multi-Ethnic Study of Atherosclerosis (MESA) is a prospective cohort study
comprised of 6814 European American (EA), African-American, Hispanic, and Asian
participants between the ages of 45 and 84 recruited at six sites from 2000 to 2002. The
six study sites were: Wake Forest University, University of Minnesota, Northwestern
University, University of California at Los Angeles, Columbia University, and Johns
Hopkins University. At baseline, participants had no clinical CVD or atrial fibrillation.
Baseline examinations included medical, demographic and lifestyle history,
measurement of coronary calcium, ventricular mass, carotid intimal-medial wall
thickness, ankle and brachial blood pressures, and standard CVD risk factors.
Fasting blood was also collected. Our study used data from 699 EA participants and
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647AA participants.
The Health, Aging and Body Composition Study (Health ABC) is a cohort study of 3075
participants age 70– 79 residing in Memphis, TN or Pittsburgh, PA who were enrolled
between 1997 and 1998. Participants were interviewed for medical and social history.
The baseline clinical exam included a general physical, tests of physical performance and
body composition as well as a blood collection. This analysis used data from 786 EA
participants and 561 AA participants.

Biomarker and Genotype Measurement
sIL-2Rα was measured in plasma by ELISA (R&D Systems) with a detectable range of
312 – 20,000pg/mL. The coefficients of variation in the current study ranged from
5.11% to 7.59%.
A total of 3388 EA and 607 AA CHS samples were genotyped using the Illumina
370CNV platform. In ancestry specific quality control (QC) analyses, SNPs were
excluded from consideration if any of the following applied: 1) minor allele frequency <
0.005, 2) missing rate across subjects > 5%, or 3) Hardy-Weinberg equilibrium p-value
< 1.0x10-5. Genotype imputation was performed to expand the coverage of common
variants in our GWAS to SNPs that were not included on the genotype panel or that were
included but were lost during QC. Ancestry-specific imputation was performed using
the software package MaCH1,2. Genotype data for 314,364 SNPs in EAs and 311,324
SNPs in AAs, after QC SNP removal, were used to impute 2.2 million SNPs from
HapMap Phase 2 and HapMap Phase 3 reference samples. For EAs, HapMap CEU
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(Phases 2 and 3) and TSI (Phase 3) reference samples were included. For AAs, CEU
(Phases 2 and 3), YRI (Phases 2 and 3), TSI (Phase 3), LWK (Phase 3), ASW (Phase 3)
reference samples were used. Finally, sets of unrelated subjects for analyses (n=3232 EA
and n=594 AA) were identified by iteratively removing one subject at a time from
subject-pairings with a global identity-by-descent (IBD) estimate > 0.10 until no subject
pairs had a global IBD estimated greater than that threshold. IBD estimation was
performed using a linkage- disequilibrium-pruned set of SNPs that had similar
frequencies in EAs and AAs (to minimize confounding of IBD with background ancestry
similarity). QC analyses and IBD estimation were performed using the software
PLINK3.
MESA participants were genotyped using the Affymetrix Human SNP array 6.0
(Affymetrix Inc. Santa Clara, CA). Ancestry-specific imputation was performed using
IMPUTE v24 using HapMap Phase 2 CEU reference samples for the European
American (EA) participants.
In the Health ABC study, genotyping was performed using the Illumina Human1MDuoBeadChip system.
Imputation in the EAs was performed using Mach version 1.0.16 using HapMap Phase 2
CEU reference samples.

Statistical Analysis
To satisfy model assumptions, sIL-2Rα was natural log-transformed for association
analyses with CVD risk factors and genetic variants. Associations between sIL-2Rα and
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quantitative traits (systolic blood pressure [SBP], LDL cholesterol, HDL cholesterol,
triglycerides, fasting glucose, fasting insulin, BMI, waist circumference, CRP, IL-6,
fibrinogen, and carotid intima media thickness [IMT]) and binary traits (diabetes mellitus
and hypertension) were analyzed using multiple linear regression and logistic regression,
respectively. Hypertension was defined as current use of antihypertensive medication or
SBP>140 and DBP>90.
Cox proportional hazards models were used to test for association between sIL-2Rα and
the risk of incident coronary heart disease (CHD), incident stroke, congestive heart failure
(CHF), CVD mortality and all-cause mortality, separately for EAs and AAs. All events
were adjudicated by an expert review panel. Incident CHD included non-procedurerelated fatal or nonfatal MI. CVD mortality included fatal events where death was
adjudicated as due to atherosclerotic CHD or cerebrovascular disease, including definite
fatal MI, definite fatal stroke and definite or probable fatal CHD5. Participants with
adjudicated baseline prevalent disease for the corresponding incident disease were
excluded from analysis (e.g. individuals with a history of myocardial infarction at first
visit were excluded from incident CHD analysis). Three progressive levels of covariate
adjustments were used to assess risk of incident events associated with sIL-2Rα levels.
The first model was minimally adjusted for the potential confounders baseline age, sex
and study site. The second model was additionally adjusted for CVD risk factors
(baseline measures of current smoking status, type 2 diabetes, hypertension, systolic blood
pressure (SBP), and low density lipoprotein (LDL) cholesterol) and baseline CVD (for the
mortality outcomes). The third model added adjustments for baseline measures of
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inflammation (C- reactive protein (CRP), interleukin-6 (IL-6), fibrinogen), and carotid
IMT.
For the genetic analyses of CHS data, the associations between sIL-2Rα and individual
genotyped and imputed SNPs, scored as dosage values (expected number of copies of the
minor alleles), were tested in linear regression models implemented in Mach2qtl1, 2.
Covariates in the regression models included age, sex, study site, and the first two
principal components (PCs), used to control for potential population substructure. PCs
were calculated using the program EIGENSOFT6, 7. The statistical significance threshold
used for defining significance was set to 5x10-8.
Targeted conditional analysis was performed in regions where multiple SNPs achieved
statistical significance to ascertain how many sIL-2Rα-associated SNPs provided
independent evidence for association in the region of interest. The conditional analysis
was performed by iteratively adding the most significant genotyped or imputed SNP in
with other model covariates and re-assessing the region for any SNP meeting genomewide significance using forward-stepwise linear regression. A series of regional association
plots showing results after each successive model iteration were constructed using the
software LocusZoom8. Given the rigidity of the forward step wise conditional analysis
approach with respect to order of SNP inclusion, we additionally applied the LASSO local
automatic regularization resample model averaging (LLARRMA) method9 to assess the
number of important SNPs across the region. Both the conditional analyses and the
LLARRMA analyses were restricted to CHS EA HapMap Phase 2 imputed data.
Estimation of sIL-2Rα phenotypic variance explained by individual SNPs was performed
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using the REG procedure with PCORR2 option in SAS. Cox proportional hazards models
were used to assess whether SNPs associated with sIL-2Rα were also associated with
incident events, both before and after adjusting for sIL-2Rα level. The significance
threshold for these analyses was set at p=0.05 and analyses were performed using STATA
statistical software.
Tests of association between imputed SNP dosage and sIL-2Rα were performed using
SNPTEST version
2.4.110 in MESA and Mach2qtl1, 2 in Health ABC. We used fixed effects inversevariance weighted meta- analysis implemented in Metal11 to combine results from CHS,
MESA and Health ABC EAs.
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Supplemental Table I: Spearman correlation coefficients for sIL2sR and continuous CVD risk factors and
subclinical CVD. *P<0.01; **P<0.001; ***P<0.0001

Baseline characteristic

Spearman
correlation
coefficient

Age, y

0.19***

Systolic blood pressure

0.037*

LDL cholesterol

-0.084***

HDL cholesterol

-0.16***

Triglycerides

0.042*

Glucose

0.038*

Insulin

0.080***

BMI

-0.038**

Waist circumference

0.018

C-reactive protein

0.17***

Interleukin-6

0.24***

Fibrinogen

0.14***

Internal carotid wall
thickness

0.13***
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Supplemental Table II. Minor allele frequencies for 5 CHS independently associated SNPs, using HapMap
data. *Not available in Hapmap, based on 1000 Genomes YRI data.

SNP
rs7911500
rs791590
rs8177757
rs10905716
rs7924005

Minor allele
T
T
T
T
C

CEU
0.14
0.16
0.04
0.24
0.19
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YRI
0
0.10
0
0.31
0.18*
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Abstract
Objective: Monocytes/macrophages play a key role in atherosclerosis and emerging
evidence supports a role for the M2 lineage in fibrosis and heart failure. CD163 is a
monocyte/macrophage specific receptor involved in the clearance and endocytosis of
hemoglobin-haptoglobin complexes, and soluble CD163 (sCD163) has been shown to
reflect macrophage activation especially of the M2 lineage. There are no large
epidemiologic studies of sCD163 with incident cardiovascular disease (CVD) events or
genetic studies of sCD163 levels. Approach and Results: We measured sCD163 in 5000
Cardiovascular Health Study (CHS) participants; 4208 European Americans (EA) and
792 African Americans (AA). At baseline, sCD163 levels were positively associated
with female sex, white race, increasing age, BMI, systolic blood pressure, C-reactive
protein, interleukin-6, and fibrinogen levels (all p<0.0001). In minimally adjusted (race,
age and sex) models we observed sCD163 levels to be strongly associated (p<0.0001)
with all-cause mortality, cardiovascular mortality, incident coronary heart disease, and
incident heart failure. After adjustment for established CVD risk factors, evidence for
association weakened for all outcomes but remained significant for incident heart failure
(p<0.005), all-cause mortality (p<0.05), and cardiovascular mortality (p<0.05). A
genome-wide association study (using Hapmap Phase 2 genotype imputation) of 2769
unrelated CHS EAs and 552 AAs identified (p<5x10-8)in EAs five variants upstream of
chromosome 2q gene MGAT5 (top result rs4954118, p=7.1x10-14) and a single variant
(rs314253, p=6.0x10-13) on chromosome 17p gene DLG4; and three variants in AAs in
the HLA region of chromosome 6 (top results rs9271366, p=1.8x10-8). Conclusions: Our
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results implicate sCD163 levels as a potentially useful biomarker for incident heart
failure, provide evidence for the association of multiple genetic variants with sCD163
levels, and support a potential role for M2 monocyte/macrophage in heart failure.
Introduction
Atherosclerosis is an inflammatory disease [1] characterized by an influx of
monocytes and lymphocytes in the arterial wall, resulting from an increase in both
circulating low-density lipoprotein (LDL) cholesterol and the oxidized LDL in the
subendothelial space. In the subendothelium space monocytes differentiate into
macrophages and infiltrate the atherosclerotic lesion, ultimately becoming cholesterolladen foam cells. M1 and M2 macrophages, defined by their expression of CD14 and
CD16 surface receptors [2], have different roles in innate immunity and express different
cell surface markers and receptors. Both M1 and M2 macrophages play a role in
atherosclerotic plaque formation and in the repair of cardiovascular injury. M1
classically activated macrophages are considered proinflammatory due to their
production of Tumor Necrosis Factor–α (TNF-α), interleukin 6 (IL-6) and IL-12; as well
as their phagocytic activity [3]. M2 alternatively activated macrophages produce IL-10
and play a role in fibrosis and immunomodulation [4]. Discovered in 1987[5], CD163 is
a 130 kDa type 1 transmembrane protein of the cysteine-rich scavenger receptor family
[6] expressed on M2 macrophages. A hemoglobin scavenger receptor, CD163 is
responsible for the clearance of hemoglobin-haptoglobin (Hb-Hp) complexes in the liver,
spleen, and plasma [7]. By removing the proinflammatory Hb-Hp complex as well as
unbound hemoglobin (Hb )[8], CD163 contributes to the anti-inflammatory or immune
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modulating response; lowering oxidative stress and the metabolism of the extracellular
Hb. Both in vitro and in vivo studies have shown that CD163 - Hb-Bp binding triggers
the release of IL-10 and carbon monoxide both of which exhibit substantial antiinflammatory effects [9]. Increased IL-10 further up-regulates CD163 and hemeoxygenase-1 expression which protects against an inflammatory response due to the
extracellular Hb [10, 11]. M2 macrophage also produce TGF-, a major stimulant of
collagen production and fibrosis [12].
A soluble form of CD163 (sCD163) is present in serum [13, 14] with a median
concentration of 1.9 mg/L in healthy individuals [13]; sCD163 contains 94% of the
membrane bound form, consisting of 945 amino acids [15]. The shedding of CD163 is
upregulated by inflammatory factors including lipopolysaccharide [16, 17], phorbol12myristate 13-acetate [18], and Fcγ receptor cross-linking [19]. The soluble form of
CD163 results from proteolytic cleavage of CD163 at the cell surface by Matrix
MetalloProteinase-9 (MMP-9) [16] and A Disintegrin and Metalloproteinase 17
(ADAM17)/TNF-α-cleaving enzyme (TACE) [20]. Elevated levels of sCD163 are
associated with a number of inflammatory conditions all involving macrophage
proliferation and activation including rheumatoid arthritis, multiple sclerosis, cancers,
sepsis, and atherosclerosis [21-24].
Despite the fact that macrophages are intimately involved in the development of
atherosclerosis as well as the fibrosis associated with heart failure, only a small number
of studies have examined the relationship between sCD163 levels and cardiovascular
disease (CVD) [21, 25, 26]. Aristoteli, et al. found an association between sCD163
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levels and the extent of atherosclerotic burden in a study of 147 coronary patients [21]
Moreno, et al. observed an association between carotid intima-thickness and elevated
sCD163 [27], and McKibben et al. found an association between sCD163 levels and
coronary artery calcium in a cohort of HIV infected and HIV uninfected men [28]. We
examined sCD163 levels in the Cardiovascular Health Study (CHS), a cohort of older
adults with follow-up for incident CVD and mortality for up to 20 years. We determined
the associations of sCD163 with known CVD risk factors and inflammatory biomarkers
measured at baseline, and with incident events. We also conducted a genome-wide
association study (GWAS) to identify genetic variants associated with sCD163 levels.
Results
Associations Between sCD163 and Baseline CVD Risk Factors and Inflammation
Biomarkers
sCD163 levels were approximately normally distributed with a mean of 787.3
ng/mL (SD=221.6 ng/mL) and a range of 145.9 – 1633.0 ng/mL. In European Americans
(EA) the mean baseline level of sCD163 was 780.0 ng/mL (SD=216.9 ng/mL) in men
and 810.9 ng/mL (SD=214.9 ng/mL) in women. In African Americans (AA) men and
women the mean sCD163 levels were 688.3 ng/mL (SD=232.6 ng/mL) and 756.0 ng/mL
(SD=242.0 ng/mL), respectively. sCD163 levels were significantly higher in older
individuals, EA as compared to AA, and women (Tables 1 and 2; all p<0.0001). In an
age-, race-, and sex-adjusted models, sCD163 levels were positively associated with type
2 diabetes, hypertension, systolic blood pressure, triglycerides, glucose, insulin, body
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mass index, waist circumference, C-reactive protein, interleukin-6, fibrinogen and
internal carotid wall thickness; while negatively associated with current smoking, and
high density lipoprotein (table 1). There was no statistically significant association
(p>0.05) with low density lipoprotein.
Incident Events Analysis
The median follow up time for the CHS participants was 13 years. There were
3392 all-cause deaths; including 1360 cardiovascular deaths. There were 1367 incident
cases of coronary heart disease, 861 cases of incident stroke, and 1421 cases of incident
heart failure (fatal and nonfatal events). In survival models minimally adjusted for age,
sex, race, and study site, baseline levels of sCD163 were significantly (all p<0.0001)
associated with increased risk for all-cause mortality, cardiovascular mortality, coronary
heart disease, and incident heart failure (Table 3). The association between baseline
sCD163 and incident stroke was significant at p<0.05. With further adjustment for
known CVD risk factors (smoking, diabetes, hypertension, systolic blood pressure, LDL
cholesterol) and BMI the association between baseline sCD163 and all-cause mortality,
cardiovascular mortality, and incident heart failure remained significant, although the
signals were attenuated. The associations with coronary heart disease and incident stroke
were no longer significant.
GWAS of sCD163 in CHS EA and AA
We conducted a race-stratified GWAS in 2769 EAs and 552 AAs from CHS that
had both sCD163 measurements and GWAS data available. The EA GWAS identified
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five significant (p<5x10-8) SNPs near the MGAT5 gene on chromosome 2; rs4954118
(p=7.11X10-14), rs3748896 (p=8.16X10-14), rs1257169 (p=1.68X10-12), rs1879018
(p=4.68X10-8), and rs1996589 (p=4.80X10-8) and one significant SNP near the DLG4
gene on chromosome 17; rs314253 (p=6.03X10-13) (Figures 1, 2, and 3). When we
modeled sCD163 levels using the five MGAT5 SNPs (Table 4) in a stepwise forward
regression analysis, we found that four SNPs, rs314253, rs4954118, rs125169, and
rs1879018, all remained significant (all p≤0.001) in a model adjusted for age, sex, and
clinic site. These four SNPs explained 5.2% of the sCD163 distribution.
Three SNPs on chromosome 6 (rs9271366, p=1.18X10-8; rs3135005, p=2.86X10-8; and
rs9270986, p=3.13X10-8) reached genome-wide significance in the AA analysis (Figures
4 and 5); all are in HLA-DRB1 region and all are highly correlated with each other (all
pairwise R2>0.90). rs9271366 accounts for approximately 5% of the variance in sCD163
in AAs.
None of the SNPs that were identified in one race/ethnic group were significant in
the other (Table 5). In AAs, the most significant MGAT5 SNP was rs1111961
(p=0.02218) and the most significant DLG4 gene SNP was rs2242449 (p=0.18554). In
EAs, the most significant HLA region SNP was rs9271366 (p=0.214). No SNPs in the
CD163 region were statistically significant at the genome-wide level in either EAs or
AAs. The most significant CD163 SNPs were rs6488429 (p=8.17x10-5) in EAs and
rs7485773 (p=4.74x10-4) in AAs.
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We searched the CARDIoGRAM+C4D database, which contains meta-analyzed
GWAS results from multiple case controls studies (total of 63,746 cases and 130,681
controls) for coronary heart disease and myocardial infarction
(http://www.cardiogramplusc4d.org) [29-31]. None of the nine SNPs identified in the
current study for sCD163 were significantly associated with case control status in
CARDIoGRAM+C4D (all p>0.05). We further examined whether any of the SNPs
identified to be associated with sCD163 level were also associated with incident events in
CHS. The two perfectly correlated MGAT5 SNPs, rs4954118 and rs3748896, were
significantly associated with incident heart failure in analyses adjusted for baseline age,
sex, and study clinic site (p=0.030). When the model was further adjusted for sCD163
level the p-value for association was slightly smaller than for the model without
adjustment for sCD163 level (p=0.006). We also conducted a Mendelian randomization
analysis, using SNP rs4954118, to test whether there was evidence for a causal
association between sCD163 levels and heart failure. The result for this analysis was not
significant (p=0.086), although it was suggestive. We observed evidence for association
between HLA SNPs rs9271366; p=0.048, rs3135005; p=0.038; with incident coronary
heart disease in AAs. When further adjusted for sCD163 level, the HLA SNPs were no
longer significantly associated with incident heart failure (both p>0.05).
Discussion
This represents the first large-scale study of sCD163, a marker of macrophage
activation, in a population based CVD study with incident events, as well as the first
GWAS for sCD163. Our major findings are: (1) sCD163 levels are associated with many
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established CVD risk factors and with carotid intima thickness; a measure of subclinical
CVD; (2) In older adults, sCD163 levels predict all-cause mortality, cardiovascular
mortality, coronary heart disease, stroke, and incident heart failure in minimally adjusted
models (P<0.0001), with a 50% greater risk of cardiovascular mortality and incident heart
failure comparing the fourth quartile to the first quartile of sCD163; (3) sCD163 levels
significantly predict all-cause mortality, cardiovascular mortality, and incident heart
failure independently of established CVD risk factors (P<0.05); (4) Genetic variants near
MGAT5 and DLG4 are associated with sCD163 in EAs and variants near HLA-DRB1 are
associated with sCD163 levels in AAs; (5) There is evidence that genetic variants
associated with sCD163 level (MGAT5 in EAs and HLA-DRB1 in AA) are also
associated with incident heart failure in older adults.
The function of sCD163 has not been well characterized but it has been postulated
that sCD163 may contribute to innate immunity by binding hemoglobin-iron in the
circulatory system thus making the iron unavailable to pathogens [17, 32]. sCD163 also
modulates the immune system by inhibiting T cell proliferation[33, 34]. Frings, et al.
have shown that it is only the soluble form of CD163 and not the membrane bound form
that inhibits T cells [33]. The work of Timmermann, et al. showed that sCD163 binds to
non-muscle myosin heavy chain in T lymphocytes causing this inhibition [35]. In vivo
studies have shown reduced T cell response and increased sCD163 expression in patients
with rheumatoid arthritis [36].
While sCD163 may directly reflect the level of M2 macrophages, sCD163 might
also result from the transition of M2 macrophages to M1 macrophages during tissue
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repair, including cardiac injury repair. Upon initial cardiac injury the percentage of
proinflammatory, M1 macrophages increase [37]. Once the acute phase of the injury has
passed, there is a transition to an increased population of anti-inflammatory, CD163
expressing macrophages essential in the remodeling phase where fibrosis and antiinflammatory cytokine expression is increased. This transition from M1 to M2
macrophages can happen through the differentiation of monocytes to M2 macrophages
and through the plasticity of the M1 macrophages transitioning to M2 macrophages [37].
As the tissue remodeling continues there is a return to the M1 and M2 macrophage
balance; it is possible that this also occurs due to macrophage plasticity and the shedding
of the CD163 receptor thereby increasing the level of circulating sCD163. Work done in
a mouse model of skeletal muscle repair shows that after the injury, pro-inflammatory,
M1 macrophages phagocytose cellular debris and then change their phenotype to
alternatively activated, anti-inflammatory, M2 macrophage promoting tissue remodeling
[38]. This study went on to show that ultimately these macrophages entered an
‘exhaustion-like state’ with no cytokine expression; if this inflammatory response was
altered muscle regeneration was negatively impacted [38]. Other studies have shown
sCD163 to be a marker of macrophage activation [39, 40], associated with noncalcified
coronary plaque [39], and over expressed in carotid plaques [41].
Our findings indicate that sCD163 is a predictor of heart failure (HR=1.50,
p<0.0001) and cardiovascular mortality (HR=1.51, p<0.0001) when comparing the first
quartile of sCD163 levels to the fourth quartile in a model adjusted for age, race, sex, and
clinic.
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Our GWAS identified three genes associated with sCD163 levels, MGAT5,
DLG4, and HLA-DRB1. MGAT5, has been associated with the M2 macrophage
phenotype and fibrosis [42] and DLG4 is involved in the cellular response to oxidative
stress, a key factor in cardiovascular diseases [43]. HLA-DRB1 is a linchpin of the
inflammatory response and has been associated with fibrosis [44]. Five of the six
significant SNPs from the EA GWAS were in MGAT5, a gene on chromosome 2, which
codes for a glycosyltransferase (mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetylglucosaminyltransferase) and has been shown to be associated with multiple sclerosis
(MS), systemic sclerosis, cancer metastasis, and liver fibrosis [45-47]. The deregulation
of the glycosyltransferase increases susceptibility to autoimmune diseases and is
associated with the severity of MS [48, 49]. Kato et al. showed in a mouse model of
scleroderma, a fibrotic disease involving vascular injury and repair, with similarities to
heart failure, that MGAT5+/+ mice had higher levels of M2 macrophages compared to
MGAT5-/- mice and that glycosylated cell surface proteins cause a shift in the macrophage
phenotype to M2 [47]. The other significant SNP found in the EA GWAS was on
chromosome 17 in DLG4, rs314253. rs314253 has been cited in the literature as being
associated with total cholesterol [50] and with the concentration of liver enzymes in
plasma [51].

DLG4 codes for post-synaptic density protein 95, a protein involved in

the regulation and structure of receptors and associated signaling proteins. DLG4 is an
important regulator of enzyme complexes essential to the cellular response to oxidative
stress and has been linked to MS, a chronic inflammatory autoimmune disease [43]. An
increase in reactive oxygen species is a key feature of the development of cardiovascular
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disease. It is interesting that both MGAT5 and DLG 4 have been linked to fibrotic
diseases. Fibrosis is a contributing factor to heart failure and cardiac senescence. It is
possible that our results showing an association of higher sCD163 levels with an
increased hazards ratio for heart failure are the result of increased fibrosis. Work by
Pinto et al. in mice showed that the M2 macrophages in the aging heart might contribute
to cardiac senescence and heart failure [52]. Further research is necessary to understand
the balance and role of the anti-inflammatory and the pro-fibrotic effects of M2
macrophages in heart failure. Further research is also necessary to understand whether
any of the variants we found have functional relevance.
The three significant results from the AA GWAS were all on chromosome 6 in
the HLA-DRB1 region. Two of the significant SNPs from the AA GWAS have been
cited in the literature; rs9271366 has been shown to be associated with Crohn’s disease,
inflammatory bowel disease [53], multiple sclerosis [54], and immunoglobulin A
deficiency [55] and rs9270986 has been found to be associated with myasthenia gravis
[37]. HLA-DRB1 is a MHC class II gene that encodes for proteins that are on particular
immune cells. HLA-DRB1 protein binds to the product of HLA-DRA forming the
functional HLA-DR antigen binding heterodimer; involved in triggering an immune
response by presenting antigen to T helper cells.
There are several limitations to this study. In our GWAS we only analyzed
common variants (minor allele frequency>0.05); rare variants may also be important in
accounting for the variability in the sCD163 levels. Given that the sample size in AAs
was considerably smaller than that in EAs, the statistical power to detect associations was
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much more limited. The Mendelian randomization analysis in EAs had limited power to
detect a causal effect, as large sample sizes are required for this approach. Lastly, our
study was focused on older adults and, therefore, our results may not be generalizable to
other populations.
In summary, our findings suggest that sCD163 may be a novel biomarker for allcause mortality, cardiovascular mortality, coronary heart disease, and in particular heart
failure in older adults. The association of sCD163 with heart failure is independent of
established CVD risk factors. We have observed several novel genetic associations for
sCD163, and association and Medelian Randomization studies suggest a possible causal
role monocyte activation, especially related to M2, in heart failure. Additional studies are
needed to assess whether sCD163 levels predict the outcomes in younger populations.
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Table 1. Association Between Soluble CD163 and Cardiovascular Risk Factors,
Inflammation Biomarkers and Measures of Subclinical Cardiovascular Disease at
the CHS Baseline Examination
Each variable was examined for association with sCD163 in a separate model, adjusting
for the variables listed (the exception is that a variable is not adjusted for itself when it is
being tested): Model A: adjusted for age, race, and sex. Model B: adjusted for age, race,
sex, smoking, diabetes mellitus, hypertension, systolic blood pressure, and BMI. β for all
measures except sex, race, diabetes mellitus, and hypertension are for a 1-SD change in
the predictor. P values: *P<0.01, **P<0.001, ***P<0.0001.

Baseline Characteristics (Mean ± SD or
%)

Model A,sCD163
β±SE

Age, y (72.5 ± 5.4)
Male sex (41.4%)
Black race (15.8%)
Current smoking (13.6%)
Type 2 diabetes (16.5%)
Hypertension (66.3%)
Systolic blood pressure, mm Hg
(138.7±19.9)
LDL cholesterol, mg/dL (130.11±35.7)
HDL cholesterol, mg/dL (54.3±15.8)
Triglycerides, mg/dL (140.7±77.7)
Glucose, mg/dL (111.4±37.2)
Insulin, IU/mL (17.3±27.4)
BMI, kg/m2 (26.7±4.7)
Waist circumference, cm (93.7±12.7)
C-reactive protein, mg/L (4.8±8.3)
Interleukin-6, pg/mL (2.2±1.9)
Fibrinogen, mg/dL (324.0±67.0)
Internal carotid wall thickness, mm
(1.4±0.6)

3.22±0.58***
-38.51±6.30***
-69.54±8.49***
-57.21±9.47***
101.28±8.51***
50.63±6.62***
0.69±0.17***

Model B,
sCD163
β±SE
3.15±064l***
-38.83±6.63***
-79.29±15.96***
-42.36±10.24***
77.20±9.20***
27.64±7.56***
0.28±0.18

-0.11±0.09
-3.23±0.21***
0.33±0.04***
1.05±0.08***
0.90±0.11***
8.30±0.67***
2.93±0.26***
3.42±0.37***
15.66±1.65***
0.30±0.05***
27.70±6.06***

-0.18±0.09
-2.74±0.23***
0.14±0.04*
0.50±0.14***
0.34±0.14
6.99±0.76***
0.74±0.47
3.03±0.42***
12.96±1.78***
0.27±0.05***
19.43±6.28*
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Table 2. Spearman correlation coefficients for sCD163 and continuous CVD risk
factors and subclinical CVD.
*P<0.01; **P<0.001; ***P<0.0001
Variables are unadjusted.

Baseline characteristic

Spearman
correlation
coefficient

Age, y

0.071***

Systolic blood pressure

0.064***

LDL cholesterol

-0.006 (0.682)

HDL cholesterol

-0.194***

Triglycerides

0.015***

Glucose

0.136***

Insulin

0.235***

BMI

0.134***

Waist circumference

0.123***

C-reactive protein

0.176***

Interleukin-6

0.211***

Fibrinogen

0.081***

Internal carotid wall
thickness
sCD14
sIL-2Rα

0.083***
0.152***
0.261***
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Table 3. Hazard Ratios Between sCD163 and Incident Events in CHS
Minimal model: Age, sex, race, clinic. Model 2: Minimal Model + smoking, diabetes, hypertension, systolic BP, LDL, BMI
Hazard ratios reflect a 1-SD change in sCD163. P values: *=P<0.05 **=P<0.005 ***=P<0.0001

Model
Minimal
2nd Q vs 1st
Q
109

All-Cause
Mortality
(5000 records
/ 3392 events)
HR (95%CI)

Cardiovascul
ar Mortality
(5000 records
/ 1360 events)
HR (95%CI)

Coronary Heart
Disease
(3963 records /
1367 events)
HR (95%CI)

1.08 (1.041.12)***

1.15 (1.091.21)***

1.10 (1.05-1.17)***

1.07 (1.00-1.15)*

1.18 (1.12-1.25)***

1.06 (0.96-1.17)

1.25 (1.061.47)*

1.26 (1.08-1.47)**

1.18 (0.97-1.44)

1.06 (0.91-1.25)

1.27 (1.081.50)**

1.23 (1.05-1.44)*

1.15 (0.94-1.40)

1.21 (1.03-1.41)*

1.23 (1.111.36)***

1.50 (1.281.76)***

1.36 (1.16-.160)***

1.22 (1.00-1.49)

1.51 (1.30-1.76)***

1.05 (1.01-1.10)*

1.08 (1.011.14)*

1.03 (0.96-1.09)

1.02 (0.94-1.10)

1.11 (1.04-1.18)**

1.11 (0.93-1.33)

1.12 (0.94-1.33)

1.04 (0.83-1.30)

0.95 (0.79-1.14)

1.20 (1.001.43)*

1.10 (0.92-1.31)

1.09 (0.88-1.36)

1.08 (0.91-1.29)

1.23 (1.031.47)*

1.09 (0.91-1.31)

1.04 (0.83-1.30)

1.22 (1.03-1.46)*

3rd Q vs 1st Q 1.07 (0.96-1.18)
4th Q vs 1st Q
Model 2

2nd Q vs 1st 1.02 (0.91-1.14)
Q
3rd Q vs 1st Q 1.05 (0.94-1.18)
4th Q vs 1st Q 1.14 (1.02-1.27)*

Stroke
(4777 records /
861 events)
HR (95%CI)

Incident Heart
Failure (4758
records / 1421
events)
HR (95%CI)

Table 4. Pairwise R2 MGAT5 SNPs EA
SNP
rs4954118
rs3748896
rs1257169
rs1879018
rs1996589

rs4954118
1
0.997
0.3747
0.0711
0.0712

rs3748896
0.997
1
0.3732
0.0705
0.0707

rs1257169
0.3747
0.3732
1
0.0268
0.0269

rs1879018
0.0711
0.0705
0.0268
1
0.9998

rs1996589
0.0712
0.0707
0.0269
0.9998
1
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Table 5. Significant SNPs in EAs and AAs
Chrm SNP
2
2
2
2
2
17
6
6
6

Gene

EA p value EA
MAF
-14
rs4954118 MGAT5
7.11x10
0.7128
rs3748896 MGAT5
8.16x10-14 0.7123
rs1257169 MGAT5
1.68x10-12 0.4548
rs1879018 MGAT5
4.68x10-8
0.6912
-8
rs1996589 MGAT5
4.80x10
0.691
-13
rs314253 DLG4
6.03x10
0.6575
rs9271366 HLA_DRB1 0.214
0.8592
rs3135005 HLA_DRB1 0.1994
0.8696
rs9270986 HLA_DRB1 0.2763
0.8558

EA β
-48.9
-48.5
-43.2
-33.9
-33.9
43.15
10.4
10.9
8.9

AA p
value
0.1867
0.1886
0.0787
0.9774
0.0383
0.8085
1.81x10-8
2.86x10-8
3.31x10-8

AA
MAF
0.7453
0.7455
0.8563
0.7190
0.4261
0.6128
0.8612
0.8647
0.8537

AA β
21.2
21.1
36.0
0.5
-30.4
3.7
115.1
114.1
113.7
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Figure 1. Manhattan Plot of CHS EA Results
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Figure 2. LocusZoom Plot of CHS EA Results Chromosome 2
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Figure 3. LocusZoom Plot of CHS EA Results Chromosome 17
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Figure 4. Manhattan Plot of CHS AA Results
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Figure 5. LocusZoom Plot of CHS AA Results Chromosome 6

METHODS sCD163 with CVD events and genome-wide scan
Study samples
The Cardiovascular Health Study (CHS) is a prospective population-based cohort study
of men and women recruited at age 65 or older at baseline. The original cohort of 5201
participants was recruited between 1988 and 1989 at four field centers: Forsyth County,
NC; Sacramento County, CA; Washington County, MD; and Pittsburgh, PA. Between
1992 and 1993, an additional 687 mostly African-American (AA) participants were
recruited for a total cohort of 5888. The baseline examination for CHS participants
included a medical history, demographic and lifestyle history, physical exam, fasting
blood collection and an assessment of vascular disease by carotid ultrasound and anklebrachial index. Our analysis was carried out on 5000 CHS participants with sCD163
measurements at baseline.

Biomarker and Genotype
Measurement

sCD163 was measured in plasma by ELISA (R&D Systems) with a detectable range of
17 – 2,000 ng/mL. The coefficients of variation in the current study ranged from 2.37%
to 3.72%.
A total of 4368 EA and 846 AA CHS samples were genotyped using the Illumina
370CNV platform. In ancestry specific quality control (QC) analyses, SNPs were
excluded from consideration if any of the following applied: 1) minor allele frequency <
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0.005, 2) missing rate across subjects > 5%, or 3) Hardy-Weinberg equilibrium p-value
< 1.0x10-5. Genotype imputation was performed to expand the coverage of common
variants in our GWAS to SNPs that were not included on the genotype panel or that
were included but were lost during QC. Ancestry-specific imputation was performed
using the software package MaCH1,2. Genotype data for 314,364 SNPs in EAs and
311,324 SNPs in AAs, after QC SNP removal, were used to impute 2.2 million SNPs
from HapMap Phase 2 and HapMap Phase 3 reference samples. For EAs, HapMap CEU
(Phases 2 and 3) and TSI (Phase 3) reference samples were included. For AAs, CEU
(Phases 2 and 3), YRI (Phases 2 and 3), TSI (Phase 3), LWK (Phase 3), ASW (Phase 3)
reference samples were used. Finally, sets of unrelated subjects for analyses (n=3232
EA and n=594 AA) were identified by iteratively removing one subject at a time from
subject-pairings with a global identity-by-descent (IBD) estimate > 0.10 until no subject
pairs had a global IBD estimated greater than that threshold. IBD estimation was
performed using a linkage- disequilibrium-pruned set of SNPs that had similar
frequencies in EAs and AAs (to minimize confounding of IBD with background
ancestry similarity). QC analyses and IBD estimation were performed using the software
PLINK3.

Statistical Analysis

Associations between sCD163 and quantitative traits (systolic blood pressure [SBP],
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LDL cholesterol, HDL cholesterol, triglycerides, fasting glucose, fasting insulin, BMI,
waist circumference, CRP, IL-6, fibrinogen, and carotid intima media thickness [IMT])
and binary traits (diabetes mellitus and hypertension) were analyzed using multiple
linear regression and logistic regression, respectively. Hypertension was defined as
current use of antihypertensive medication or SBP>140 and DBP>90.
Cox proportional hazards models were used to test for association between sCD163 and
the risk of incident coronary heart disease (CHD), incident stroke, congestive heart
failure (CHF), CVD mortality and all-cause mortality, separately for EAs and AAs. All
events were adjudicated by an expert review panel. Incident CHD included nonprocedure-related fatal or nonfatal MI. CVD mortality included fatal events where death
was adjudicated as due to atherosclerotic CHD or cerebrovascular disease, including
definite fatal MI, definite fatal stroke and definite or probable fatal CHD4. Participants
with adjudicated baseline prevalent disease for the corresponding incident disease were
excluded from analysis (e.g. individuals with a history of myocardial infarction at first
visit were excluded from incident CHD analysis). Three progressive levels of covariate
adjustments were used to assess risk of incident events associated with sCD163 levels.
The first model was minimally adjusted for the potential confounders baseline age, sex
and study site. The second model was additionally adjusted for CVD risk factors
(baseline measures of current smoking status, type 2 diabetes, hypertension, systolic
blood pressure (SBP), and low density lipoprotein (LDL) cholesterol) and baseline CVD
(for the mortality outcomes). The third model added adjustments for baseline measures
of inflammation (C- reactive protein (CRP), interleukin-6 (IL-6), fibrinogen), and carotid
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IMT.
For the genetic analyses of CHS data, the associations between sCD163 and individual
genotyped and imputed SNPs, scored as dosage values (expected number of copies of the
minor alleles), were tested in linear regression models implemented in Mach2qtl1, 2.
Covariates in the regression models included age, sex, study site, and the first two
principal components (PCs), used to control for potential population substructure. PCs
were calculated using the program EIGENSOFT 5,6. The statistical significance
threshold used for defining significance was set to 5x10-8. A series of regional
association plots showing results were constructed using the software LocusZoom7.
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Chapter 4: Summary and a Look to the Future.
The major cause of CVD is atherosclerosis, a chronic inflammatory process
involving both the innate and adaptive immune systems. Animal work and epidemiology
have elucidated many of the underlying processes in the development of atherosclerotic
plaques. However, CVD is complex and has other contributing factors including genetic
predisposition, modifiable and non-modifiable risk factors, environmental exposures and
the interactions of all of these. Our studies of both sIL-2Rα and sCD163 provide further
evidence of both the adaptive and innate immune systems involvement in CVD. Our
analysis of sIL-2Rα levels in CHS was the first large-scale assessment of sIL-2Rα for
association with CVD traits and events; and the first GWAS for SNPs associated with
sIL-2Rα levels. When we analyzed data from CHS our results found that sIL-2Rα, a
surrogate for T lymphocyte activity, is a novel biomarker for all-cause mortality,
cardiovascular mortality, stroke, and heart failure in older adults as well as associated
with other CVD risk factors. We also identified 52 SNPs in chromosome 10 at and near
the IL2RA gene that had genome wide significance for association with sIL-2Rα levels in
European Americans. A number of these SNPs were previously associated with type 1
diabetes mellitus and multiple sclerosis. These findings combined with our results
provides additional support for the position that T cell activation plays an important role
in several disorders including, but not limited to, CVD.
We cannot identify the casual SNP(s) based on our current analyses; further highdensity genotyping of the chromosome 10 region will be necessary. While sIL-2Rα
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levels may be a novel biomarker in older adults, further studies are necessary to verify the
generalizability to other populations. Continued investigation into the genetic control of
IL-2/IL-2R interplay with regard to T-cell differentiation and cytokine production is also
needed.
Our work on sCD163 represents the first large-scale study in a population-based
cohort with incident events and GWAS data. We found sCD163, a marker of
macrophage activation, to be associated with many CVD risk factors and to be an
independent predictor of all-cause mortality, cardiovascular mortality, and incident heart
failure in older adults. Our GWAS found genetic variants in the genes MGAT5 and
ASGR1/DLG4 to be associated with sCD163 levels in European Americans while
variants in HLA-DRB1 were associated with sCD163 levels in African Americans; no
SNPs in the region of CD163 reached genome-wide significance. Mendelian
Randomization analysis indicated that the variants in MGAT5 in European Americans
and those in HLA-DRB1 in African Americans associated with sCD163 levels also
associated with incident heart failure in older adults. As for sIL2Rα, additional genetic
work is necessary to identify the functional variant for sCD163 levels.
Atherosclerosis prevention and treatment is a prime example of translational
science. Basic science research in mice and rabbits combined with studies of
biochemical pathways and epidemiological and genetic studies in cohorts have informed
clinical practice. To date much of atherosclerosis prevention has fallen under the
umbrella of Public Health with the focus being on lifestyle changes as a management of
risk factors including smoking, hypertension, hyperlipidemia, diabetes mellitus, high
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blood pressure, sedentary lifestyle, and diet. Research into the development and
progression of atherosclerosis led to an understanding of the importance of cholesterol in
the process. In the 1950’s the work of Konrad E. Bloch, Feodor Lynen, John Cornforth,
and George Popják elaborated the biosynthetic pathway of cholesterol leading to the
search for cholesterol synthesis inhibitors [1]. With the Food and Drug Administration
approval of the Merck drug lovastatin, it became the first commercially available drug for
lowering LDL cholesterol [2] moving atherosclerosis prevention from Public Health to a
more targeted approach. Since the advent of statins, many approaches to the prevention
of CVD have been examined. In addition to cholesterol lowering medications, other
treatments include anti-platelet drugs to prevent platelet clumping, beta-blockers,
angiotensin-converting enzyme inhibitors, and calcium channel blockers. Other
treatments have targeted the inflammatory system. Work by Huber et al. in mice showed
that increased levels of IL-6 resulted in a large increase in size of fatty lesions [3]. Down
regulating, the immune response or biasing the immune response toward an
antithrombotic response might slow plaque progression. A recent report on the effects of
cyclodextrin in mice found that the drug increases cholesterol solubility and essentially
reprograms the macrophages to improve cholesterol efflux and reduce atherosclerotic
plaque size [4]. Genetic associations and the continued search for casual variants will
lead to targeted, personalized, therapies for atherosclerosis. The identification of loss of
function variants and their association with a decreased risk of heart disease in genes
PCSK9, NPC1L1, APOC3, and APOA5 [5] give encouragement to other potential
therapies and the translation of bench science to clinical practice.

124

Continued

investigation of both sIL-2Rα and sCD163, markers of T-cell and monocyte
differentiation, in animal models and cohort studies may lead to opportunities for the
prevention of atherosclerosis and/or treatment through an increased understanding of both
the biology and genetics of both the innate and adaptive immune responses in
atherosclerosis.
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